FI108797B - Menetelmiä humanisoitujen immunoglobuliinien tuottamiseksi sekä menetelmissä käyttökelpoinen polynukleotidimolekyyli ja solulinja - Google Patents
Menetelmiä humanisoitujen immunoglobuliinien tuottamiseksi sekä menetelmissä käyttökelpoinen polynukleotidimolekyyli ja solulinja Download PDFInfo
- Publication number
- FI108797B FI108797B FI912436A FI912436A FI108797B FI 108797 B FI108797 B FI 108797B FI 912436 A FI912436 A FI 912436A FI 912436 A FI912436 A FI 912436A FI 108797 B FI108797 B FI 108797B
- Authority
- FI
- Finland
- Prior art keywords
- immunoglobulin
- human
- antibody
- humanized
- donor
- Prior art date
Links
- 108060003951 Immunoglobulin Proteins 0.000 title claims abstract description 133
- 102000018358 immunoglobulin Human genes 0.000 title claims abstract description 133
- 238000000034 method Methods 0.000 title claims description 40
- 108091033319 polynucleotide Proteins 0.000 title claims description 9
- 239000002157 polynucleotide Substances 0.000 title claims description 9
- 102000040430 polynucleotide Human genes 0.000 title claims description 9
- 229940072221 immunoglobulins Drugs 0.000 title description 32
- 150000001413 amino acids Chemical class 0.000 claims abstract description 84
- 230000027455 binding Effects 0.000 claims abstract description 31
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims abstract description 27
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims abstract description 17
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims abstract description 15
- 108010002350 Interleukin-2 Proteins 0.000 claims abstract description 15
- 102000000588 Interleukin-2 Human genes 0.000 claims abstract description 15
- 102000005962 receptors Human genes 0.000 claims abstract description 10
- 108020003175 receptors Proteins 0.000 claims abstract description 10
- 102000055277 human IL2 Human genes 0.000 claims abstract 2
- 210000004027 cell Anatomy 0.000 claims description 76
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 51
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 22
- 239000000427 antigen Substances 0.000 claims description 22
- 108091007433 antigens Proteins 0.000 claims description 22
- 102000036639 antigens Human genes 0.000 claims description 22
- 238000004519 manufacturing process Methods 0.000 claims description 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 11
- 230000001225 therapeutic effect Effects 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 4
- 230000000903 blocking effect Effects 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 2
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 claims 3
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 56
- 102000004169 proteins and genes Human genes 0.000 abstract description 28
- 241001529936 Murinae Species 0.000 abstract description 12
- 150000007523 nucleic acids Chemical class 0.000 abstract description 3
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 abstract 4
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 108091034117 Oligonucleotide Proteins 0.000 description 26
- 239000000203 mixture Substances 0.000 description 20
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 19
- 239000013612 plasmid Substances 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 201000010099 disease Diseases 0.000 description 14
- 239000012634 fragment Substances 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 description 11
- 239000002773 nucleotide Substances 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 238000009472 formulation Methods 0.000 description 9
- 238000010561 standard procedure Methods 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000002596 immunotoxin Substances 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 229940127089 cytotoxic agent Drugs 0.000 description 7
- 230000002637 immunotoxin Effects 0.000 description 7
- 229940051026 immunotoxin Drugs 0.000 description 7
- 231100000608 immunotoxin Toxicity 0.000 description 7
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 239000002254 cytotoxic agent Substances 0.000 description 6
- 231100000599 cytotoxic agent Toxicity 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 108020004511 Recombinant DNA Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 108090001008 Avidin Proteins 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 108010004729 Phycoerythrin Proteins 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000002285 radioactive effect Effects 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 3
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 3
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 3
- 108010039491 Ricin Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000011651 chromium Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 241000557626 Corvus corax Species 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- WUAPFZMCVAUBPE-NJFSPNSNSA-N 188Re Chemical compound [188Re] WUAPFZMCVAUBPE-NJFSPNSNSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000157426 Pernis Species 0.000 description 1
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 108700033844 Pseudomonas aeruginosa toxA Proteins 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241001474728 Satyrodes eurydice Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 201000006966 adult T-cell leukemia Diseases 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- JCXGWMGPZLAOME-AKLPVKDBSA-N bismuth-212 Chemical compound [212Bi] JCXGWMGPZLAOME-AKLPVKDBSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- -1 etc. Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000012414 sterilization procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940002004 the magic bullet Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/087—Herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/088—Varicella-zoster virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29097588A | 1988-12-28 | 1988-12-28 | |
US29097588 | 1988-12-28 | ||
US31025289A | 1989-02-13 | 1989-02-13 | |
US31025289 | 1989-02-13 | ||
PCT/US1989/005857 WO1990007861A1 (en) | 1988-12-28 | 1989-12-28 | CHIMERIC IMMUNOGLOBULINS SPECIFIC FOR p55 TAC PROTEIN OF THE IL-2 RECEPTOR |
US8905857 | 1989-12-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
FI912436A0 FI912436A0 (fi) | 1991-05-20 |
FI108797B true FI108797B (fi) | 2002-03-28 |
Family
ID=26966505
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI912436A FI108797B (fi) | 1988-12-28 | 1991-05-20 | Menetelmiä humanisoitujen immunoglobuliinien tuottamiseksi sekä menetelmissä käyttökelpoinen polynukleotidimolekyyli ja solulinja |
Country Status (32)
Country | Link |
---|---|
EP (6) | EP2341080A1 (es) |
JP (6) | JP2828340B2 (es) |
KR (1) | KR0178385B1 (es) |
CN (1) | CN1057013C (es) |
AT (2) | ATE183753T1 (es) |
AU (1) | AU647383B2 (es) |
BG (1) | BG61095B2 (es) |
CA (2) | CA2328851C (es) |
CZ (1) | CZ418691A3 (es) |
DD (1) | DD296964A5 (es) |
DE (14) | DE98204240T1 (es) |
DK (2) | DK119191A (es) |
ES (5) | ES2081974T5 (es) |
FI (1) | FI108797B (es) |
FR (1) | FR14C0070I1 (es) |
HK (1) | HK1014718A1 (es) |
HR (1) | HRP920500B1 (es) |
HU (1) | HU211174A9 (es) |
IE (1) | IE20000331A1 (es) |
IL (2) | IL162181A (es) |
LU (8) | LU90411I2 (es) |
MC (1) | MC2146A1 (es) |
NL (8) | NL990020I2 (es) |
NO (9) | NO310473B1 (es) |
NZ (2) | NZ314793A (es) |
PT (1) | PT92758B (es) |
RU (1) | RU2126046C1 (es) |
SG (1) | SG78258A1 (es) |
SI (1) | SI8912489B (es) |
WO (1) | WO1990007861A1 (es) |
YU (1) | YU48700B (es) |
ZA (1) | ZA899956B (es) |
Families Citing this family (977)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5800815A (en) * | 1903-05-05 | 1998-09-01 | Cytel Corporation | Antibodies to P-selectin and their uses |
US5851526A (en) * | 1985-04-19 | 1998-12-22 | Ludwig Institute For Cancer Research | Methods of treating colon cancer utilizing tumor-specific antibodies |
US5449760A (en) * | 1987-12-31 | 1995-09-12 | Tanox Biosystems, Inc. | Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US7247453B1 (en) * | 1988-12-30 | 2007-07-24 | Oklahoma Medical Research Foundation | Calcium binding recombinant antibody against protein C |
DE3900534A1 (de) * | 1989-01-10 | 1990-07-12 | Boehringer Mannheim Gmbh | Diagnostischer nachweis unter verwendung von chimaeren antikoerpern |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US6750325B1 (en) | 1989-12-21 | 2004-06-15 | Celltech R&D Limited | CD3 specific recombinant antibody |
GR1001050B (el) * | 1990-01-09 | 1993-04-28 | Protein Design Labs Inc | Νεος il-2 υποδοχευς ιδιαζοντων ανθρωπινων ανοσοσφαιρινων. |
HUT60768A (en) | 1990-03-16 | 1992-10-28 | Sandoz Ag | Process for producing cd25 fixing molecules |
GB9020282D0 (en) | 1990-09-17 | 1990-10-31 | Gorman Scott D | Altered antibodies and their preparation |
US5858725A (en) * | 1990-10-10 | 1999-01-12 | Glaxo Wellcome Inc. | Preparation of chimaeric antibodies using the recombinant PCR strategy |
US5994510A (en) * | 1990-12-21 | 1999-11-30 | Celltech Therapeutics Limited | Recombinant antibodies specific for TNFα |
DK0531472T3 (da) * | 1991-03-06 | 2003-12-01 | Merck Patent Gmbh | Humaniserede monoklonale antistoffer |
NZ241855A (en) * | 1991-03-07 | 1994-04-27 | Gen Hospital Corp | Use of therapeutic cells to obtain cellular response to infection, tumours or autoimmune-generated cells, cells with chimaeric receptors (with binding component and destruction signal), dna encoding the receptor, vectors and antibodies to receptor |
JP3213314B2 (ja) * | 1991-04-05 | 2001-10-02 | ボード・オブ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・ワシントン | 幹細胞因子レセプターに対するモノクローナル抗体 |
DK0628639T3 (da) * | 1991-04-25 | 2000-01-24 | Chugai Pharmaceutical Co Ltd | Rekonstitueret humant antistof mod human interleukin-6-receptor |
EP0519596B1 (en) * | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
GB9115010D0 (en) * | 1991-07-11 | 1991-08-28 | Wellcome Found | Antibody |
GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
MX9204374A (es) * | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
US5709860A (en) * | 1991-07-25 | 1998-01-20 | Idec Pharmaceuticals Corporation | Induction of cytotoxic T-lymphocyte responses |
US6136310A (en) | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
US5756096A (en) * | 1991-07-25 | 1998-05-26 | Idec Pharmaceuticals Corporation | Recombinant antibodies for human therapy |
BR9206310A (pt) * | 1991-07-25 | 1995-04-25 | Idec Pharma Corp | Indução de respostas citotóxicas de linfócitos T. |
US6685939B2 (en) | 1991-08-14 | 2004-02-03 | Genentech, Inc. | Method of preventing the onset of allergic disorders |
US6329509B1 (en) * | 1991-08-14 | 2001-12-11 | Genentech, Inc. | Anti-IgE antibodies |
DK0528767T3 (da) * | 1991-08-21 | 2000-04-17 | Novartis Ag | antistofderivater |
GB9120467D0 (en) * | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
JP3024311B2 (ja) * | 1991-10-03 | 2000-03-21 | 味の素株式会社 | Il−2受容体重鎖に結合するポリペプチド |
US7070777B1 (en) | 1991-11-15 | 2006-07-04 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting inflammation with an antibody that binds the 5C8 protein |
US5474771A (en) | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
US5817310A (en) | 1991-12-02 | 1998-10-06 | Cor Therapeutics, Inc. | Inhibitory immunoglobulin polypeptides to human PDGF beta receptor |
JPH05244982A (ja) * | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化b−b10 |
WO1993011794A1 (en) * | 1991-12-13 | 1993-06-24 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
US5869619A (en) * | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
US5777085A (en) * | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
US5824307A (en) | 1991-12-23 | 1998-10-20 | Medimmune, Inc. | Human-murine chimeric antibodies against respiratory syncytial virus |
ATE503496T1 (de) * | 1992-02-06 | 2011-04-15 | Novartis Vaccines & Diagnostic | Biosynthetisches bindeprotein für tumormarker |
GB9203459D0 (en) * | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
US5714350A (en) * | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5387676A (en) * | 1992-03-11 | 1995-02-07 | Ciba Corning Diagnostics Corp. | MN gene and protein |
US7381803B1 (en) | 1992-03-27 | 2008-06-03 | Pdl Biopharma, Inc. | Humanized antibodies against CD3 |
US6129914A (en) * | 1992-03-27 | 2000-10-10 | Protein Design Labs, Inc. | Bispecific antibody effective to treat B-cell lymphoma and cell line |
US6033667A (en) * | 1992-05-05 | 2000-03-07 | Cytel Corporation | Method for detecting the presence of P-selectin |
US5397703A (en) * | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
US5874082A (en) * | 1992-07-09 | 1999-02-23 | Chiron Corporation | Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation |
US5639641A (en) * | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US6066718A (en) * | 1992-09-25 | 2000-05-23 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
US5958708A (en) * | 1992-09-25 | 1999-09-28 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
GB9223377D0 (en) * | 1992-11-04 | 1992-12-23 | Medarex Inc | Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes |
CA2149326C (en) * | 1992-11-13 | 2007-04-17 | Mitchell E. Reff | Fully impaired consensus kozak sequences for mammalian expression |
US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
PL174721B1 (pl) * | 1992-11-13 | 1998-09-30 | Idec Pharma Corp | Przeciwciało monoklonalne anty-CD20 |
US5648267A (en) * | 1992-11-13 | 1997-07-15 | Idec Pharmaceuticals Corporation | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same |
US7744877B2 (en) | 1992-11-13 | 2010-06-29 | Biogen Idec Inc. | Expression and use of anti-CD20 Antibodies |
US5804187A (en) * | 1992-11-16 | 1998-09-08 | Cancer Research Fund Of Contra Costa | Modified antibodies with human milk fat globule specificity |
ES2137354T3 (es) | 1993-01-12 | 1999-12-16 | Biogen Inc | Moleculas de anticuerpo anti-vla4 recombinante. |
US5730979A (en) * | 1993-03-05 | 1998-03-24 | Universite Catholique Delouvain | LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation |
US5817311A (en) * | 1993-03-05 | 1998-10-06 | Universite Catholique De Louvain | Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies |
US5951983A (en) * | 1993-03-05 | 1999-09-14 | Universite Catholique De Louvain | Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies |
EP0804235A4 (en) * | 1993-05-04 | 2001-09-19 | Aeres Biomedical Ltd | ANTIBODIES AGAINST SELECTIN P AND USES THEREOF |
JPH08510909A (ja) * | 1993-05-28 | 1996-11-19 | ザ スクリップス リサーチ インスティチュート | Cd14媒介細胞活性化を抑制するための方法および組成物 |
WO1994028159A1 (fr) * | 1993-05-31 | 1994-12-08 | Chugai Seiyaku Kabushiki Kaisha | Anticorps humain reconstruit contre l'interleukine-6 humaine |
US6180377B1 (en) * | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
UA48940C2 (uk) * | 1993-09-07 | 2002-09-16 | Смітклайн Бічам Корпорейшн | Рекомбінатні il4 антитіла, які використовуються для лікування il4-опосередкованих порушень |
US5928904A (en) * | 1993-09-07 | 1999-07-27 | Smithkline Beecham Corporation | DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
US20020193575A1 (en) | 1993-09-07 | 2002-12-19 | Smithkline Beecham P.L.C. | Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
US5914110A (en) * | 1993-09-07 | 1999-06-22 | Smithkline Beecham Corporation | Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
WO1995014041A1 (fr) | 1993-11-19 | 1995-05-26 | Chugai Seiyaku Kabushiki Kaisha | Anticorps humain reconstitue contre des cellules medulloblastomateuses humaines |
WO1995015181A1 (en) * | 1993-11-30 | 1995-06-08 | Protein Design Labs, Inc. | Reperfusion therapy using antibodies to l-selectin |
GB9325182D0 (en) * | 1993-12-08 | 1994-02-09 | T Cell Sciences Inc | Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions |
US7435802B2 (en) | 1994-01-25 | 2008-10-14 | Elan Pharaceuticals, Inc. | Humanized anti-VLA4 immunoglobulins |
WO1995019790A1 (en) * | 1994-01-25 | 1995-07-27 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule vla-4 |
US5840299A (en) * | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
EP0753065B1 (en) | 1994-03-29 | 2003-05-14 | Celltech Therapeutics Limited | Antibodies against e-selectin |
US5635597A (en) * | 1994-05-27 | 1997-06-03 | Affymax Technologies, N.V. | Peptides that bind IL-2 receptors |
US5622701A (en) | 1994-06-14 | 1997-04-22 | Protein Design Labs, Inc. | Cross-reacting monoclonal antibodies specific for E- and P-selectin |
USRE39548E1 (en) * | 1994-06-17 | 2007-04-03 | Celltech R&D Limited | Interleukin-5 specific recombinant antibodies |
GB9412230D0 (en) * | 1994-06-17 | 1994-08-10 | Celltech Ltd | Interleukin-5 specific recombiant antibodies |
US6048972A (en) * | 1994-07-13 | 2000-04-11 | Chugai Pharmaceutical Co., Ltd. | Recombinant materials for producing humanized anti-IL-8 antibodies |
DE4425115A1 (de) * | 1994-07-15 | 1996-01-18 | Boehringer Mannheim Gmbh | Verfahren zur Modifizierung der Stabilität von Antikörpern |
EP0696455A1 (en) * | 1994-08-11 | 1996-02-14 | Cellena (Cell Engineering) A.G. | Transferrin compositions to alleviate the side effects of cytotoxic drugs |
US8771694B2 (en) * | 1994-08-12 | 2014-07-08 | Immunomedics, Inc. | Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells |
US5707621A (en) * | 1994-08-31 | 1998-01-13 | Chugai Pharmaceutical Co., Ltd. | Supression of nephritis-induced protein excretion by anti-IL-8 |
US6309636B1 (en) * | 1995-09-14 | 2001-10-30 | Cancer Research Institute Of Contra Costa | Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides |
US5693323A (en) * | 1994-12-23 | 1997-12-02 | Smithkline Beecham Corporation | Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
US7153508B2 (en) | 1995-06-07 | 2006-12-26 | Biogen Idec Inc. | Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4 |
US5811524A (en) * | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
AU6171196A (en) * | 1995-06-07 | 1996-12-30 | Sloan-Kettering Institute For Cancer Research | Therapeutic uses of ta99 |
US6113898A (en) * | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
US7175847B1 (en) | 1995-06-07 | 2007-02-13 | Biogen Idec Inc. | Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4 |
US6001358A (en) * | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
US6440418B1 (en) | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
GB9600660D0 (en) | 1996-01-12 | 1996-03-13 | Ciba Geigy Ag | Protein |
AU2527397A (en) * | 1996-03-13 | 1997-10-01 | Protein Design Labs, Inc. | Fas ligand fusion proteins and their uses |
US5882644A (en) * | 1996-03-22 | 1999-03-16 | Protein Design Labs, Inc. | Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof |
US6713305B1 (en) | 1996-04-29 | 2004-03-30 | Novartis Ag | Metastasis-associated antigen and antibodies thereto |
CA2257357C (en) | 1996-06-07 | 2010-04-13 | Neorx Corporation | Humanized antibodies with modified glycosylation |
US6534311B2 (en) | 1996-07-24 | 2003-03-18 | Novartis Ag | Drosophila melanogaster p70S6 kinase |
US6833255B1 (en) | 1996-07-24 | 2004-12-21 | Novartis, Ag | Drosophila melanogaster p70 S6 kinase |
US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
CA2264968A1 (en) * | 1996-09-02 | 1998-03-12 | Sumitomo Electric Industries, Ltd. | Humanized immunoglobulin reacting specifically with fas ligand or active fragments thereof and region inducing apoptosis originating in fas ligand |
US6013256A (en) * | 1996-09-24 | 2000-01-11 | Protein Design Labs, Inc. | Method of preventing acute rejection following solid organ transplantation |
CN100335501C (zh) | 1996-09-26 | 2007-09-05 | 中外制药株式会社 | 抗人副甲状腺激素相关蛋白的抗体 |
UA76934C2 (en) | 1996-10-04 | 2006-10-16 | Chugai Pharmaceutical Co Ltd | Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody |
US7883872B2 (en) | 1996-10-10 | 2011-02-08 | Dyadic International (Usa), Inc. | Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose |
US7910096B2 (en) | 1996-11-15 | 2011-03-22 | Trustees Of Tufts College | Human neutralizing antibodies against hemolytic uremic syndrome |
US20020160005A1 (en) | 1996-11-15 | 2002-10-31 | Trustees Of Tufts College | Human neutralizing antibodies against hemolytic urmec syndrome |
EP2314695A3 (en) | 1996-12-23 | 2011-12-21 | Immunex Corporation | Ligand for receptor activator of NF-kappa B, ligand is member of TNF superfamily |
US6262238B1 (en) * | 1997-01-14 | 2001-07-17 | Roche Diagnostic, Gmbh | Process for modifying the stability of antibodies |
US6596850B1 (en) | 1998-01-30 | 2003-07-22 | Ixsys, Incorporated | Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same |
US6590079B2 (en) | 1997-01-30 | 2003-07-08 | Ixsys, Incorporated | Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same |
US20030109680A1 (en) | 2001-11-21 | 2003-06-12 | Sunol Molecular Corporation | Antibodies for inhibiting blood coagulation and methods of use thereof |
US5986065A (en) | 1997-03-10 | 1999-11-16 | Sunol Molecular Corporation | Antibodies for inhibiting blood coagulation and methods of use thereof |
US20060235209A9 (en) | 1997-03-10 | 2006-10-19 | Jin-An Jiao | Use of anti-tissue factor antibodies for treating thromboses |
US7749498B2 (en) | 1997-03-10 | 2010-07-06 | Genentech, Inc. | Antibodies for inhibiting blood coagulation and methods of use thereof |
IL123756A0 (en) * | 1997-03-21 | 1998-10-30 | Sankyo Co | Humanized anti-human FAS antibody |
US6972323B1 (en) | 1997-04-01 | 2005-12-06 | Sankyo Company, Limited | Anti-Fas antibodies |
US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
EP1787999B1 (en) | 1997-04-07 | 2010-08-04 | Genentech, Inc. | Anti-VEGF antibodies |
US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
US7365166B2 (en) | 1997-04-07 | 2008-04-29 | Genentech, Inc. | Anti-VEGF antibodies |
DE69837707T2 (de) * | 1997-05-15 | 2008-01-10 | Chugai Seiyaku K.K. | Heilmittel für kachexie |
JP2002512624A (ja) * | 1997-05-21 | 2002-04-23 | バイオベーション リミテッド | 非免疫原性タンパク質の製造方法 |
EP1019082B2 (en) | 1997-10-02 | 2008-06-04 | Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. | Use of a colony stimulating factor (csf) for enhancing collateral growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
CN1277632A (zh) * | 1997-10-03 | 2000-12-20 | 中外制药株式会社 | 天然人源化抗体 |
US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
EP1745799B1 (en) | 1998-03-04 | 2015-09-02 | The Trustees of The University of Pennsylvania | Compositions and methods of treating tumors |
PL343322A1 (en) | 1998-04-03 | 2001-08-13 | Chugai Pharmaceutical Co Ltd | Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody |
CN1689646A (zh) | 1998-08-11 | 2005-11-02 | 拜奥根Idec公司 | 包括施用抗-cd20抗体的b-细胞淋巴瘤联合疗法 |
JP4689781B2 (ja) * | 1998-09-03 | 2011-05-25 | 独立行政法人科学技術振興機構 | アミノ酸輸送蛋白及びその遺伝子 |
EP2065050A1 (en) | 1998-09-14 | 2009-06-03 | Board of Regents, The University of Texas System | Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists |
DE69922978T2 (de) | 1998-10-06 | 2005-12-08 | Emalfarb, Mark Aaron, Jupiter | Transformationsystem in filamentösen fungiziden chrysosporium-wirtszellen |
EP1939215A1 (en) | 1998-10-22 | 2008-07-02 | The University of Montana | Omp85 proteins of neisseria gonorrhoeae and neisseria meningitidis, compositions containing same and methods of use thereof |
KR101092132B1 (ko) | 1998-11-09 | 2011-12-12 | 바이오겐 아이덱 인크. | 키메라 항-cd20항체를 이용한 순환성 종양세포와 관련된 혈액학적 악성종양의 치료법 |
GB9825632D0 (en) | 1998-11-23 | 1999-01-13 | Novartis Ag | Organic compounds |
US20030035798A1 (en) | 2000-08-16 | 2003-02-20 | Fang Fang | Humanized antibodies |
AU767066B2 (en) | 1999-03-03 | 2003-10-30 | Curis, Inc. | Methods of modulating lipid metabolism and storage |
GB9906380D0 (en) * | 1999-03-19 | 1999-05-12 | Melvin William T | Monoclonal antibodies specific for cypibi |
DE60020955T2 (de) | 1999-04-22 | 2006-05-11 | Biogen Idec Ma Inc., Cambridge | Verfahren zur behandlung einer fibrose unter verwendung eines antagonisten der integrin alpha-4 untereinheit |
IT1306704B1 (it) | 1999-05-26 | 2001-10-02 | Sirs Societa Italiana Per La R | Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf. |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
CA2375827C (en) | 1999-06-01 | 2017-01-10 | Biogen, Inc. | A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders |
US7144991B2 (en) | 1999-06-07 | 2006-12-05 | Aletheon Pharmaceuticals, Inc. | Streptavidin expressed gene fusions and methods of use thereof |
US6531580B1 (en) | 1999-06-24 | 2003-03-11 | Ixsys, Inc. | Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same |
TWI255718B (en) | 1999-07-02 | 2006-06-01 | Chugai Pharmaceutical Co Ltd | Ameliorative agent for low vasopressin concentration |
US8557244B1 (en) | 1999-08-11 | 2013-10-15 | Biogen Idec Inc. | Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody |
EP1238985B1 (en) * | 1999-09-30 | 2008-03-05 | Kyowa Hakko Kogyo Co., Ltd. | Human type complementarity determining region transplantation antibody against ganglioside gd3 and derivatives of antibody against ganglioside gd3 |
US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
CA3016482A1 (en) | 1999-11-30 | 2001-06-07 | Mayo Foundation For Medical Education And Research | B7-h1, a novel immunoregulatory molecule |
ES2415708T3 (es) | 1999-12-16 | 2013-07-26 | Biogen Idec Ma Inc. | Métodos de tratamiento de la lesión isquémica o hemorrágica del sistema nervioso central mediante el uso de antagonistas anti-integrina alfa4 |
AU785038B2 (en) | 2000-01-27 | 2006-08-31 | Applied Molecular Evolution, Inc. | Ultra high affinity neutralizing antibodies |
WO2001064751A2 (en) | 2000-03-01 | 2001-09-07 | Medimmune, Inc. | High potency recombinant antibodies and method for producing them |
ATE373719T1 (de) * | 2000-02-03 | 2007-10-15 | Millennium Pharm Inc | Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung |
NZ520789A (en) | 2000-02-11 | 2005-01-28 | Biogen Inc | Heterologous polypeptide of the TNF family |
CZ306683B6 (cs) | 2000-02-24 | 2017-05-03 | Washington University | Léčivo pro prevenci nebo léčení preklinické nebo klinické Alzheimerovy nemoci |
AU4574501A (en) | 2000-03-17 | 2001-10-03 | Millennium Pharm Inc | Method of inhibiting stenosis and restenosis |
US20010046496A1 (en) | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
ATE420661T1 (de) | 2000-04-28 | 2009-01-15 | Chugai Pharmaceutical Co Ltd | Zellproliferation-inhibitoren |
US7030219B2 (en) | 2000-04-28 | 2006-04-18 | Johns Hopkins University | B7-DC, Dendritic cell co-stimulatory molecules |
AU6110301A (en) | 2000-04-29 | 2001-11-12 | Univ Iowa Res Found | Diagnostics and therapeutics for macular degeneration-related disorders |
TWI318983B (en) | 2000-05-02 | 2010-01-01 | Uab Research Foundation | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
US7279160B2 (en) | 2000-05-02 | 2007-10-09 | The Uab Research Foundation | Combinations of DR5 antibodies and other therapeutic agents |
US7476383B2 (en) | 2000-05-02 | 2009-01-13 | The Uab Research Foundation | Antibody selective for DR4 and uses thereof |
GB0013810D0 (en) | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
ATE327004T1 (de) | 2000-10-02 | 2006-06-15 | Chiron Corp | Verfahren zur therapie von b-zellmalignitäten unter verwendung von antagonistischen antikörpern gegen cd40 |
US6989247B2 (en) | 2000-11-28 | 2006-01-24 | Celltech R & D, Inc. | Compositions and methods for diagnosing or treating psoriasis |
US7179900B2 (en) | 2000-11-28 | 2007-02-20 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
PT1379557E (pt) * | 2001-04-06 | 2008-12-29 | Univ Bristol | Utilização de moléculas de ligação a cd25 em doentes resistentes a esteróides |
AR036330A1 (es) | 2001-04-13 | 2004-09-01 | Biogen Inc | Un anticuerpo anti-vla-1, una composicion que lo incluye, un acido nucleico aislado consistente en una secuencia de codificacion de dicho anticuerpo, un metodo para determinar el nivel de vla-1 en un tejido, celulas del hibridoma de dicho anticuerpo, una computadora que produce una representacion tr |
US6972324B2 (en) | 2001-05-18 | 2005-12-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Antibodies specific for CD44v6 |
MXPA03010523A (es) * | 2001-05-18 | 2004-07-01 | Boehringer Ingelheim Pharma | Anticuerpos especificos para cd44v6. |
US7541443B2 (en) * | 2001-06-14 | 2009-06-02 | Tolerrx, Inc. | Anti-CD4 antibodies |
ATE440869T1 (de) | 2001-06-20 | 2009-09-15 | Fibron Ltd | Fgfr3 blockierende antikírper, verfahren zum screening darauf und verwendungen davon |
US20030013081A1 (en) | 2001-06-26 | 2003-01-16 | Olson William C. | Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection |
JP4675512B2 (ja) * | 2001-07-10 | 2011-04-27 | 三井化学株式会社 | 熱殺菌方法 |
CA2898314A1 (en) | 2001-07-19 | 2003-07-31 | Perian Therapeutics, Inc. | Multimeric proteins and methods of making and using same |
EP1420032B2 (en) † | 2001-08-03 | 2015-12-16 | Medical & Biological Laboratories Co., Ltd. | Antibody recognizing gm1 ganglioside-bound amyloid beta-protein and dna encoding the antibody |
EP1944040B1 (en) | 2001-08-17 | 2012-08-01 | Washington University | Assay method for Alzheimer's disease |
LT1434871T (lt) | 2001-09-20 | 2017-04-10 | Immunex Corporation | Heteromerinius polipeptidus ekspresuojančių ląstelių atranka |
EP1431310A4 (en) | 2001-09-25 | 2005-03-23 | Immuno Biological Lab Co Ltd | ANTI-OSTEOPONTIN RECOMBINANT ANTIBODY AND USE THEREOF |
GB0124317D0 (en) | 2001-10-10 | 2001-11-28 | Celltech R&D Ltd | Biological products |
US20030190705A1 (en) * | 2001-10-29 | 2003-10-09 | Sunol Molecular Corporation | Method of humanizing immune system molecules |
US7524502B2 (en) * | 2001-11-12 | 2009-04-28 | Merck Patent Gmbh | Modified anti-TNF alpha antibody |
EP1944043A1 (en) | 2001-11-21 | 2008-07-16 | The Trustees of the University of Pennsylvania | Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use |
NZ564586A (en) | 2001-11-21 | 2009-09-25 | Univ Pennsylvania | Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use |
EP2990394A1 (en) | 2001-11-30 | 2016-03-02 | Biogen MA Inc. | Antibodies against monocyte chemotactic proteins |
EP2298817A1 (en) | 2001-12-03 | 2011-03-23 | Alexion Pharmaceuticals, Inc. | Hybrid antibodies |
US7393648B2 (en) | 2001-12-03 | 2008-07-01 | Alexion Pharmaceuticals, Inc. | Hybrid antibodies |
GB0129105D0 (en) | 2001-12-05 | 2002-01-23 | Celltech R&D Ltd | Expression control using variable intergenic sequences |
KR101033196B1 (ko) * | 2002-02-14 | 2011-05-09 | 이뮤노메딕스, 인코오포레이티드 | 항-cd20 항체 및 그 융합 단백질 및 이들의 이용방법 |
PT1478738E (pt) * | 2002-02-22 | 2009-02-16 | Progenics Pharm Inc | Anticorpo anti-ccr5 |
ES2531852T3 (es) | 2002-02-25 | 2015-03-20 | Biogen Idec Ma Inc. | Administración de agentes para el tratamiento de la inflamación |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
RS52488B (en) | 2002-03-13 | 2013-02-28 | Biogen Idec Ma Inc. | ANTI-ALFAvBETA6 ANTITELA |
PT1495056E (pt) | 2002-03-20 | 2011-03-29 | Ucb Pharma Sa | Métodos de análise |
CA2480059C (en) | 2002-03-22 | 2015-11-24 | Amrad Operations Pty. Ltd. | Monoclonal antibody against interleukin-13 receptor alpha 1 (il-13r.alpha.1) |
GB0210121D0 (en) | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
AU2003241449B2 (en) | 2002-05-14 | 2009-03-05 | Dsm Ip Assets B.V. | Carotene synthase gene and uses therefor |
ES2370710T3 (es) | 2002-05-28 | 2011-12-22 | Ucb Pharma, S.A. | ISÓMERO POSICIONAL DE PEG DE UN ANTICUERPO ANTI-TNFalfa (CDP870). |
EP1513554B9 (en) * | 2002-05-30 | 2011-11-09 | Macrogenics, Inc. | Cd16a binding proteins and use for the treatment of immune disorders |
US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
GB0213745D0 (en) | 2002-06-14 | 2002-07-24 | Univ Edinburgh | Enzyme |
US7544483B2 (en) | 2002-06-14 | 2009-06-09 | Monier Tadros | Method for the production of protamine |
US7575742B2 (en) * | 2002-06-28 | 2009-08-18 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating autoimmune diseases with interferon-beta and IL-2R antagonist |
US9535076B2 (en) | 2002-09-12 | 2017-01-03 | The Regents Of The University Of California | Methods and compositions for eliciting an amyloid-selective immune response |
US7432351B1 (en) | 2002-10-04 | 2008-10-07 | Mayo Foundation For Medical Education And Research | B7-H1 variants |
GB0228832D0 (en) | 2002-12-10 | 2003-01-15 | Novartis Ag | Organic compound |
TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
ES2401136T3 (es) | 2002-11-15 | 2013-04-17 | Genmab A/S | Anticuerpos monoclonales humanos contra CD25 |
CA2537263C (en) | 2002-11-27 | 2017-05-30 | Minerva Biotechnologies Corporation | Techniques and compositions for the diagnosis and treatment of cancer (muc1) |
CN103833854B (zh) | 2002-12-16 | 2017-12-12 | 健泰科生物技术公司 | 免疫球蛋白变体及其用途 |
AU2004205684A1 (en) | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
MXPA05007823A (es) | 2003-01-24 | 2005-10-18 | Elan Pharm Inc | Composicion y tratamiento de enfermedades desmielizantes y paralisis por administracion de agentes remielinizantes. |
EP1460088A1 (en) | 2003-03-21 | 2004-09-22 | Biotest AG | Humanized anti-CD4 antibody with immunosuppressive properties |
US7321065B2 (en) | 2003-04-18 | 2008-01-22 | The Regents Of The University Of California | Thyronamine derivatives and analogs and methods of use thereof |
MXPA05011409A (es) | 2003-04-23 | 2005-12-12 | Medarex Inc | Composiciones y metodos para la terapia de enfermedad inflamatoria intestinal. |
WO2004094473A2 (en) * | 2003-04-23 | 2004-11-04 | Medarex, Inc. | Humanized antibodies to interferon alpha receptor-1 (ifnar-1) |
US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
HUE034320T2 (en) | 2003-05-19 | 2018-02-28 | Prothena Biosciences Ltd | Truncated fragments of alpha-synuclein in lewy-body disease |
WO2005003175A2 (en) | 2003-06-13 | 2005-01-13 | Biogen Idec Ma Inc. | Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof |
US8153410B2 (en) | 2003-07-07 | 2012-04-10 | Fox Chase Cancer Center | Alternate morpheein forms of allosteric proteins as a target for the development of bioactive molecules |
US20060162014A1 (en) | 2003-07-07 | 2006-07-20 | Jaffe Eileen K | Alternate morpheeins of allosteric proteins as a target for the development of bioactive molecules |
SI2784084T2 (sl) | 2003-07-08 | 2024-02-29 | Novartis Pharma Ag | Antagonistična protitelesa proti IL-17 A/F heterolognim polipeptidom |
KR101254371B1 (ko) | 2003-07-18 | 2013-05-02 | 암젠 프레몬트 인코포레이티드 | 간세포 성장인자에 결합하는 분리된 항체 |
US7834155B2 (en) | 2003-07-21 | 2010-11-16 | Immunogen Inc. | CA6 antigen-specific cytotoxic conjugate and methods of using the same |
US20060228350A1 (en) * | 2003-08-18 | 2006-10-12 | Medimmune, Inc. | Framework-shuffling of antibodies |
GB0321997D0 (en) | 2003-09-19 | 2003-10-22 | Novartis Ag | Organic compound |
CN101133083A (zh) | 2003-11-11 | 2008-02-27 | 中外制药株式会社 | 人源化的抗cd47抗体 |
AU2004290059A1 (en) | 2003-11-12 | 2005-05-26 | Albert Einstein College Of Medicine Of Yeshiva University | Novel sequences encoding hepatitis C virus glycoproteins |
EP2070947B1 (en) | 2003-12-05 | 2014-06-11 | multimmune GmbH | Therapeutic and diagnostic anti-Hsp70 antibodies |
JP2008504218A (ja) | 2003-12-08 | 2008-02-14 | モルフォテック、インク. | Pms2と特異的に結合する抗体 |
US20080025913A1 (en) | 2003-12-15 | 2008-01-31 | Bowdish Katherine S | Novel Anti-Dc-Sign Antibodies |
ITRM20030601A1 (it) * | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
JP5422101B2 (ja) | 2004-01-07 | 2014-02-19 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | M−csf特異的モノクローナル抗体およびその使用 |
EP1712566A4 (en) | 2004-01-19 | 2007-09-12 | Medical & Biol Lab Co Ltd | INFLAMMATORY CYTOKINE INHIBITOR |
JP2007521811A (ja) | 2004-01-30 | 2007-08-09 | ダナ ファーバー キャンサー インスティテュート | 放射線又は遺伝毒性物質曝露の測定及び定量方法 |
PL1713503T3 (pl) | 2004-02-10 | 2014-02-28 | Univ Colorado Regents | Hamowanie czynnika B, alternatywny szlak dopełniacza i związane z tym sposoby |
EP1716179A2 (en) | 2004-02-12 | 2006-11-02 | Morphotek, Inc. | Monoclonal antibodies that specifically bind to folate receptor alpha |
TWI359026B (en) | 2004-02-12 | 2012-03-01 | Sankyo Co | Pharmaceutical composition for the osteoclast rela |
EP1717250A4 (en) | 2004-02-20 | 2008-10-01 | Immuno Biological Lab Co Ltd | MONOCLONAL ANTIBODY AND ITS USE |
EP1730196B1 (en) | 2004-03-12 | 2010-12-22 | Vasgene Therapeutics, Inc. | Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth |
MXPA06010673A (es) | 2004-03-19 | 2007-06-20 | Amgen Inc | Reduccion del riesgo de anticuerpos humanos anti-humano a traves de manipulacion del gen v. |
US7625549B2 (en) | 2004-03-19 | 2009-12-01 | Amgen Fremont Inc. | Determining the risk of human anti-human antibodies in transgenic mice |
MY162179A (en) | 2004-04-01 | 2017-05-31 | Elan Pharm Inc | Steroid sparing agents and methods of using same |
CA2562038C (en) | 2004-04-02 | 2017-04-25 | The Regents Of The University Of California | Methods and compositions for treating and preventing disease associated with .alpha.v.beta.5 integrin |
US8492106B2 (en) | 2004-05-24 | 2013-07-23 | Universitat Zu Koln | Identification methods for ergothioneine transporter modulators and therapeutic uses thereof |
EP1602926A1 (en) | 2004-06-04 | 2005-12-07 | University of Geneva | Novel means and methods for the treatment of hearing loss and phantom hearing |
PT2662390T (pt) | 2004-06-21 | 2017-10-09 | Squibb & Sons Llc | Anticorpos contra recetor 1 do interferão alfa e as suas utilizações |
GB0414054D0 (en) | 2004-06-23 | 2004-07-28 | Owen Mumford Ltd | Improvements relating to automatic injection devices |
GEP20105059B (en) | 2004-07-26 | 2010-08-10 | Biogen Idec Inc | Anti-cd154 antibodies |
GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
EA013752B1 (ru) | 2004-08-09 | 2010-06-30 | Элан Фармасьютикалз, Инк. | Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний |
CA2478458A1 (en) | 2004-08-20 | 2006-02-20 | Michael Panzara | Treatment of pediatric multiple sclerosis |
FI20041204A0 (fi) | 2004-09-16 | 2004-09-16 | Riikka Lund | Menetelmät immuunivälitteisiin sairauksiin liittyvien uusien kohdegeenien hyödyntämiseksi |
AU2005291486A1 (en) | 2004-10-01 | 2006-04-13 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Novel antibodies directed to the mammalian EAG1 ion channel protein |
AU2005295038B2 (en) | 2004-10-06 | 2012-05-17 | Mayo Foundation For Medical Education And Research | B7-H1 and methods of diagnosis, prognosis, and treatment of cancer |
NZ554520A (en) | 2004-10-22 | 2010-03-26 | Amgen Inc | Methods for refolding of recombinant antibodies |
NZ554725A (en) | 2004-10-25 | 2009-10-30 | Merck & Co Inc | Anti-ADDL antibodies and uses thereof |
WO2006055871A2 (en) | 2004-11-19 | 2006-05-26 | Biogen Idec Ma Inc. | Treatment for multiple sclerosis |
AR052051A1 (es) | 2004-12-15 | 2007-02-28 | Neuralab Ltd | Anticuerpos ab humanizados usados en mejorar la cognicion |
ATE423140T1 (de) | 2005-01-05 | 2009-03-15 | F Star Biotech Forsch & Entw | Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften |
EP1855715B1 (en) | 2005-01-27 | 2013-03-13 | Children's Hospital & Research Center at Oakland | Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
EP2302076B1 (en) | 2005-02-14 | 2014-11-12 | University of Iowa Research Foundation | Methods and reagents for treatment and diagnosis of age-related macular degeneration |
DK2529619T3 (en) | 2005-02-17 | 2016-01-11 | Biogen Ma Inc | Treatment of neurological disorders |
US8048992B2 (en) | 2005-02-28 | 2011-11-01 | Institute For Antibodies Co., Ltd. | Anti-IgSF4 antibody and utilization of the same |
JP2008531719A (ja) | 2005-03-02 | 2008-08-14 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Th2介在性状態の治療のためのKIM−1抗体 |
EP2322560B1 (en) | 2005-03-10 | 2013-09-04 | Morphotek, Inc. | Anti-mesothelin antibodies |
JP2008532559A (ja) | 2005-03-19 | 2008-08-21 | メディカル リサーチ カウンシル | ウイルス感染の治療及び予防又は治療及び予防の改善 |
AU2006230099B2 (en) | 2005-03-25 | 2012-04-19 | Gitr, Inc. | GITR binding molecules and uses therefor |
EP2527365A3 (en) | 2005-03-30 | 2013-02-20 | Minerva Biotechnologies Corporation | Proliferation of MUC1 expressing cells |
DK1875244T3 (en) | 2005-03-30 | 2019-04-29 | Minerva Biotechnologies Corp | Proliferation of MUC1-Expressing Cells |
CN102989012B (zh) | 2005-03-31 | 2015-05-13 | 通用医疗公司 | 监测和调制hgf/hgfr活性 |
EP2645106B1 (en) | 2005-04-04 | 2017-06-14 | Biogen MA Inc. | Methods for evaluating an immune response to a therapeutic agent |
CA2607455A1 (en) | 2005-04-22 | 2006-11-02 | Morphotek, Inc. | Antibodies with immune effector activity and that internalize in endosialin-positive cells |
CA2607444C (en) | 2005-04-22 | 2015-03-10 | Morphotek, Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
WO2006117910A1 (ja) | 2005-04-28 | 2006-11-09 | Mochida Pharmaceutical Co., Ltd. | 抗血小板膜糖蛋白質ⅵモノクローナル抗体 |
US8034902B2 (en) | 2005-05-04 | 2011-10-11 | Quark Pharmaceuticals, Inc. | Recombinant antibodies against CD55 and CD59 and uses thereof |
DK2559690T3 (en) | 2005-05-10 | 2016-04-25 | Incyte Holdings Corp | Modulators of indoleamine 2,3-dioxygenase and methods of use thereof |
AU2006247188A1 (en) | 2005-05-18 | 2006-11-23 | Children's Hospital & Research Center At Oakland | Methods and compositions for immunizing against chlamydia infection |
US8858935B2 (en) | 2005-05-19 | 2014-10-14 | Amgen Inc. | Compositions and methods for increasing the stability of antibodies |
CN103505728A (zh) | 2005-05-26 | 2014-01-15 | 科罗拉多大学评议会法人机构 | 用于治疗外伤性脑损伤、脊髓损伤及相关病症的补体旁路抑制 |
CN103242447B (zh) | 2005-05-27 | 2016-04-27 | 比奥根Ma公司 | 结合tweak的抗体 |
EP2364998A1 (en) | 2005-06-16 | 2011-09-14 | The Feinstein Institute for Medical Research | Antibodies against HMGB1 and fragments thereof |
ES2547463T3 (es) | 2005-06-17 | 2015-10-06 | Merck Sharp & Dohme Corp. | Moléculas de unión a ILT3 y usos de las mismas |
KR20140139618A (ko) * | 2005-06-21 | 2014-12-05 | 조마 (유에스) 엘엘씨 | IL-1β 결합성 항체 및 그의 단편 |
CN104072614B (zh) | 2005-07-08 | 2017-04-26 | 生物基因Ma公司 | 抗-αvβ6 抗体及其用途 |
FR2888850B1 (fr) | 2005-07-22 | 2013-01-11 | Pf Medicament | Nouveaux anticorps anti-igf-ir et leurs applications |
JP2009514790A (ja) | 2005-07-22 | 2009-04-09 | プロジェニクス・ファーマスーティカルズ・インコーポレイテッド | Hiv−1−感染患者におけるウイルス負荷を減少させる方法 |
EP2311876A3 (en) | 2005-07-28 | 2011-04-27 | Novartis AG | M-CSF-specific monoclonal antibody and uses thereof |
US8193328B2 (en) | 2005-09-08 | 2012-06-05 | Philadelphia Health & Education Corporation | Identification of modulators of serine protease inhibitor Kazal and their use as anti-cancer and anti-viral agents |
EP1934605B1 (en) | 2005-09-22 | 2014-03-26 | Prosci Incorporated | Glycosylated polypeptides produced in yeast mutants and methods of use thereof |
EP1948680A4 (en) | 2005-10-28 | 2010-01-13 | Univ California | METHOD AND COMPOUNDS FOR DETECTING AND ISOLATING LYMPHOMA CELLS |
AU2006307018B2 (en) | 2005-10-28 | 2012-10-25 | Meiji Seika Kaisha, Ltd. | Outer coat protein PA5158 of Pseudomonas aeruginosa |
EP1948235B1 (en) | 2005-11-01 | 2013-08-28 | AbbVie Biotechnology Ltd | Methods for determining efficacy of adalimumab in subjects having ankylosing spondylitis using ctx-ii and mmp3 as biomarkers |
JP2009516513A (ja) | 2005-11-21 | 2009-04-23 | ラボラトワール セローノ ソシエテ アノニム | ハイブリッド抗原結合分子の組成物及び製造方法並びにその使用 |
IL297746A (en) † | 2005-11-30 | 2022-12-01 | Abbvie Inc | Monoclonal antibodies against amyloid beta protein and uses thereof |
DOP2006000277A (es) | 2005-12-12 | 2007-08-31 | Bayer Pharmaceuticals Corp | Anticuerpos anti mn y métodos para su utilización |
EP1984522B1 (en) | 2006-01-18 | 2010-08-11 | The General Hospital Corporation | Methods of increasing lymphatic function |
EP1987066B1 (en) | 2006-02-22 | 2010-12-29 | University of Zürich | Methods for treating demyelinating diseases |
US20070218065A1 (en) | 2006-03-10 | 2007-09-20 | Jaspers Stephen R | Antibodies that bind both il-17a and il-17f and methods of using the same |
WO2007108152A1 (ja) | 2006-03-23 | 2007-09-27 | Tohoku University | 高機能性二重特異性抗体 |
AU2007232894B2 (en) | 2006-03-30 | 2013-01-31 | Meiji Seika Kaisha, Ltd. | Pseudomonas aeruginosa outer membrane protein PA0427 |
CN101454025B (zh) | 2006-04-05 | 2014-01-01 | 艾伯维生物技术有限公司 | 抗体纯化 |
CA2564435A1 (en) | 2006-04-10 | 2007-10-10 | Abbott Biotechnology Ltd. | Methods for monitoring and treating intestinal disorders |
EP2666472A3 (en) | 2006-04-10 | 2014-04-02 | Abbott Biotechnology Ltd | Uses and compositions for treatment of psoriatic arthritis |
EP2666478A3 (en) | 2006-04-10 | 2014-10-22 | AbbVie Biotechnology Ltd | Uses and compositions for treatment of psoriasis |
EP2839843B1 (en) | 2006-05-25 | 2018-06-20 | Biogen MA Inc. | VLA-1 antagonist for use in treating stroke |
BRPI0711229A2 (pt) | 2006-05-31 | 2013-01-08 | Astellas Pharma Inc | anticorpo humanizado da osteopontina anti-humana, polinucleotÍdeo, vetor de expressço, cÉlula hospedeita, mÉtodo para produzir um anticorpo humanizado de osteopontina anti-humana, fÁrmaco terapÊutico, mÉtodo para prevenir ou tratar doenÇa autoimune e uso do anticorpo humanizado de oesteopontina anti-humana |
CA2653628C (en) | 2006-06-01 | 2015-07-14 | Elan Pharmaceuticals, Inc. | Neuroactive fragments of app |
WO2007144893A2 (en) | 2006-06-15 | 2007-12-21 | Fibron Ltd. | Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof |
WO2008094176A2 (en) | 2006-06-19 | 2008-08-07 | Tolerx, Inc. | Ilt3 binding molecules and uses therefor |
TWI527603B (zh) | 2006-06-30 | 2016-04-01 | 艾伯維生物技術有限責任公司 | 自動注射裝置 |
AT503889B1 (de) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | Multivalente immunglobuline |
JP2009542196A (ja) | 2006-07-07 | 2009-12-03 | インターセル アーゲー | 小型の化膿連鎖球菌抗原およびそれらの使用 |
SG173364A1 (en) | 2006-07-10 | 2011-08-29 | Biogen Idec Inc | Compositions and methods for inhibiting growth of smad4-deficient cancers |
WO2008007648A1 (fr) | 2006-07-10 | 2008-01-17 | Institute For Antibodies Co., Ltd. | Procédé de classification d'antigène, procédé d'identification d'antigène, procédé d'obtention d' un ensemble d'antigènes ou d'anticorps, procédés de construction d'un panel d'anticorps, anticorps et ens |
EP2420252A1 (en) | 2006-08-04 | 2012-02-22 | Novartis AG | EPHB3-specific antibody and uses thereof |
EP2056709A4 (en) | 2006-08-11 | 2013-05-01 | Univ New Jersey Med | DOUBLE-SENSITIZER WITH LUMINESCENCE COMPOUNDS, CONJUGATES AND USE |
RS53092B (en) | 2006-08-18 | 2014-06-30 | Novartis Ag | PRLR-SPECIFIC ANTIBODY AND ITS USES |
EP2500414A1 (en) | 2006-09-13 | 2012-09-19 | Abbott Laboratories | Cell culture improvements |
CN101663390B (zh) | 2006-09-13 | 2013-10-23 | Abbvie公司 | 使用非动物源水解产物的分批补料细胞培养方法 |
JPWO2008032833A1 (ja) | 2006-09-14 | 2010-01-28 | 株式会社医学生物学研究所 | Adcc活性を増強させた抗体及びその製造方法 |
FR2906533B1 (fr) | 2006-09-28 | 2013-02-22 | Pf Medicament | Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations |
JP5570218B2 (ja) | 2006-11-03 | 2014-08-13 | ユースリー ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング | Fgfr4抗体 |
WO2008056833A1 (fr) | 2006-11-10 | 2008-05-15 | Livtech Inc. | Anticorps anti-humain spécifiques de dlk1 présentant une activité anti-tumorale in vivo |
EP2395022A1 (en) | 2006-11-17 | 2011-12-14 | Novartis AG | Lingo binding molecules and pharmaceutical use thereof |
EP1923069A1 (en) | 2006-11-20 | 2008-05-21 | Intercell AG | Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto |
US8288110B2 (en) | 2006-12-04 | 2012-10-16 | Perkinelmer Health Sciences, Inc. | Biomarkers for detecting cancer |
MX2009006034A (es) | 2006-12-07 | 2009-10-12 | Novartis Ag | Anticuerpos antagonistas contra ephb3. |
EP2505651A3 (en) | 2006-12-10 | 2013-01-09 | Dyadic International, Inc. | Isolated fungus with reduced protease activity |
WO2008083169A2 (en) | 2006-12-26 | 2008-07-10 | The Johns Hopkins University | Compositions and methods for the treatment of immunologic disorders |
US7989173B2 (en) | 2006-12-27 | 2011-08-02 | The Johns Hopkins University | Detection and diagnosis of inflammatory disorders |
JP5481199B2 (ja) | 2006-12-27 | 2014-04-23 | ザ ジョンズ ホプキンス ユニバーシティー | 炎症および自己免疫疾患を治療するための組成物および方法 |
ES2533566T3 (es) | 2006-12-29 | 2015-04-13 | The Regents Of The University Of Colorado, A Body Corporate | Diana diagnóstica y terapéutica para enfermedades autoinmunitarias y sus usos |
PL2099826T3 (pl) | 2007-01-05 | 2014-04-30 | Univ Zuerich | Przeciwciało przeciwko beta-amyloidowi i jego zastosowania |
EP2269624A3 (en) | 2007-01-12 | 2012-08-08 | Intercell AG | Protective proteins of S. agalactiae, combinations thereof and methods of using the same |
WO2008098139A2 (en) | 2007-02-07 | 2008-08-14 | The Regents Of The University Of Colorado | Axl tyrosine kinase inhibitors and methods of making and using the same |
CN101657721B (zh) | 2007-02-16 | 2018-02-23 | 基酶有限公司 | 鉴定甲状腺疾病风险的方法 |
DK3067066T3 (da) | 2007-02-23 | 2019-05-20 | Prothena Biosciences Ltd | Forebyggelse og behandling af synukleinopatisk og amyloidogenisk sygdom |
HUE043966T2 (hu) | 2007-02-23 | 2019-09-30 | Prothena Biosciences Ltd | Szinukleinopátiás és amiloidogén betegség megelõzése és kezelése |
JP2010519256A (ja) | 2007-02-23 | 2010-06-03 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | 免疫疾患を治療するために、HLA−E/Qa−1拘束性CD8+T細胞制御性経路を活性化または遮断する方法 |
RU2488593C2 (ru) | 2007-03-13 | 2013-07-27 | Юниверсити Оф Цюрих | Человеческое опухолеспецифическое моноклональное антитело |
MY166021A (en) | 2007-03-22 | 2018-05-21 | Biogen Ma Inc | Binding proteins,including antibodies,antibody derivatives and antibody fragments,that specifically bind cd154 and uses thereof |
US7807382B2 (en) | 2007-04-05 | 2010-10-05 | Morphotek, Inc. | Methods for inhibiting the binding of endosialin to ligands |
EP2150564A2 (en) | 2007-04-27 | 2010-02-10 | ZymoGenetics, Inc. | Antagonists to il-17a, il-17f, and il-23p19 and methods of use |
CA2685805A1 (en) | 2007-05-02 | 2008-11-13 | Intercell Ag | Klebsiella antigens |
EP2160403B1 (en) | 2007-05-11 | 2018-08-08 | Genzyme Corporation | Methods of producing a secreted protein |
EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
US7709215B2 (en) | 2007-06-01 | 2010-05-04 | Cytonics Corporation | Method for diagnosing and treating acute joint injury |
WO2008154543A2 (en) | 2007-06-11 | 2008-12-18 | Abbott Biotechnology Ltd. | Methods for treating juvenile idiopathic arthritis |
US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
BRPI0814252B8 (pt) | 2007-06-14 | 2021-05-25 | Biogen Idec Inc | composição farmacêutica aquosa estável compreendendo natalizumabe, dose unitária, e seringa pré-cheia |
WO2008155291A2 (en) | 2007-06-18 | 2008-12-24 | Intercell Ag | Chlamydia antigens |
EP3241842B1 (en) | 2007-06-26 | 2024-01-31 | F-star Therapeutics Limited | Display of binding agents |
CN101888855A (zh) | 2007-06-27 | 2010-11-17 | 阿斯比奥制药株式会社 | 含有由抗骨膜素的外显子-17编码的肽的抗体的癌症治疗剂 |
EP2014681A1 (en) | 2007-07-12 | 2009-01-14 | Pierre Fabre Medicament | Novel antibodies inhibiting c-met dimerization, and uses thereof |
EP3124046B1 (en) | 2007-07-12 | 2019-12-25 | GITR, Inc. | Combination therapies employing gitr binding molecules |
JP2010533649A (ja) | 2007-07-13 | 2010-10-28 | ザ ジョンズ ホプキンス ユニバーシティー | B7−dc改変体 |
SI2185198T1 (sl) | 2007-08-02 | 2015-04-30 | Gilead Biologics, Inc. | Inhibitorji LOX in LOXL2 ter njihova uporaba |
ES2618316T3 (es) | 2007-08-30 | 2017-06-21 | Daiichi Sankyo Company, Limited | Anticuerpo anti EPHA2 |
EP2186892A1 (en) * | 2007-09-06 | 2010-05-19 | Osaka University | Anti-cd20 monoclonal antibodies |
WO2009033071A2 (en) | 2007-09-07 | 2009-03-12 | Dyadic International, Inc. | Novel fungal enzymes |
WO2009033743A1 (en) | 2007-09-13 | 2009-03-19 | University Of Zurich Prorektorat Forschung | Monoclonal amyloid beta (abeta)-specific antibody and uses thereof |
CA2698809C (en) | 2007-09-14 | 2023-10-17 | Amgen Inc. | Homogeneous antibody populations |
PT2238166E (pt) | 2007-10-05 | 2014-02-11 | Genentech Inc | Utilização do anticorpo anti-amilóide beta em doenças oculares |
CA2698326C (en) | 2007-10-11 | 2015-03-17 | Daiichi Sankyo Company, Limited | Antibody targeting osteoclast-related protein siglec-15 |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
EP2210901A4 (en) | 2007-10-19 | 2012-04-25 | Immunas Pharma Inc | ANTIBODY CAPABLE OF BINDING SPECIFICALLY TO OLIGOMER A, AND USE THEREOF |
CA2704447A1 (en) | 2007-11-01 | 2009-05-07 | University Of Iowa Research Foundation | Predicting amd with snps within or near c2, factor b, plekha1, htra1, prelp, or loc387715 |
WO2009056509A1 (en) | 2007-11-02 | 2009-05-07 | Novartis Ag | Improved nogo-a binding molecules and pharmaceutical use thereof |
EP2902495B1 (en) | 2007-11-09 | 2019-12-25 | The Salk Institute for Biological Studies | Use of tam receptor activators as immunosuppressors |
US8933202B2 (en) | 2007-11-12 | 2015-01-13 | U3 Pharma Gmbh | AXL antibodies |
AU2008331906B2 (en) | 2007-11-28 | 2014-03-06 | The Trustees Of The University Of Pennsylvania | Simian E adenovirus SAdV-39 |
EP2463362B1 (en) | 2007-11-28 | 2017-11-08 | The Trustees Of The University Of Pennsylvania | Simian subfamily c adenovirus SAdv-31 and uses thereof |
US8815237B2 (en) | 2007-12-05 | 2014-08-26 | Massachusetts Institute Of Technology | Aglycosylated immunoglobulin mutants |
US8779088B2 (en) | 2007-12-17 | 2014-07-15 | Marfl Ab | Vaccine for the treatment of Mycobacterium related disorders |
US20100291070A1 (en) | 2007-12-25 | 2010-11-18 | Meiji Seika Kaisha, Ltd. | Type iii secretion system component protein pa1698 of pseudomonas aeruginosa |
SG186689A1 (en) | 2007-12-28 | 2013-01-30 | Univ Tennessee Res Foundation | Treatment and prophylaxis of amyloidosis |
MX2010007551A (es) | 2008-01-11 | 2010-11-30 | Synovex Corp | Antagonistas de la cadherina-11 y metodos para el tratamiento de trastornos inflamatorios de las articulacion. |
EP2245156A4 (en) * | 2008-01-11 | 2011-02-02 | Gene Techno Science Co Ltd | HUMANIZED ANTI-9 INTEGRIN ANTIBODIES AND USES THEREOF |
BRPI0905656B8 (pt) | 2008-01-11 | 2021-05-25 | Astellas Pharma Inc | anticorpo humanizado a9-integrina anti-humana, fármaco terapêutico para artrite rematóide e uso do anticorpo humanizado a9-integrina anti-humana. |
ES2617604T3 (es) | 2008-02-08 | 2017-06-19 | Immunas Pharma, Inc. | Anticuerpos capaces de unirse específicamente a oligómeros de beta amiloides, y su utilización |
CA2716928C (en) | 2008-03-04 | 2018-04-10 | The Trustees Of The University Of Pennsylvania | Simian adenoviruses sadv-36,-42.1, -42.2, and -44 and uses thereof |
BRPI0909179A2 (pt) | 2008-03-13 | 2015-08-25 | Biotest Ag | Composição farmacêutica, e, método de tratamento de uma doença autoimune. |
MX2010010026A (es) | 2008-03-13 | 2011-03-21 | Biotest Ag | Agente para tratar enfermedad. |
EP2265643B1 (en) | 2008-03-13 | 2016-10-19 | Biotest AG | Dosing regimen for treating psoriasis and rheumatoid arthritis |
EP2664339A3 (en) | 2008-03-17 | 2013-12-11 | Universitätsklinikum Münster | YopM as delivery vehicle for cargo molecules and as biological therapeutic for immunomodulation of inflammatory reactions |
EP2265634A2 (en) | 2008-03-17 | 2010-12-29 | Intercell AG | Peptides protective against s. pneumoniae and compositions, methods and uses relating thereto |
EP2275537B1 (en) | 2008-03-17 | 2014-12-24 | Livtech Inc. | Anti-human dlk-1 antibody having anti-tumor activity in vivo |
EP2260863A1 (en) | 2008-03-27 | 2010-12-15 | Takara Bio, Inc. | Prophylactic/therapeutic agent for infectious disease |
CN102056626B (zh) | 2008-04-11 | 2016-07-06 | 西雅图遗传学公司 | 胰腺癌、卵巢癌和其它癌症的检测和治疗 |
AU2009242453B2 (en) | 2008-05-02 | 2014-12-04 | Seagen Inc. | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
EP2113255A1 (en) | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
EP3384919A1 (en) | 2008-06-02 | 2018-10-10 | Dana Farber Cancer Institute, Inc. | Cs1 peptides |
EP2319869B1 (en) | 2008-06-20 | 2016-08-17 | National University Corporation Okayama University | ANTIBODY AGAINST OXIDIZED LDL/ß²GPI COMPLEX AND USE OF THE SAME |
PT2307457T (pt) | 2008-06-25 | 2018-10-16 | Esbatech Alcon Biomed Res Unit | Anticorpos estáveis e solúveis que inibem o tnf |
SI3628686T1 (sl) | 2008-06-25 | 2022-01-31 | Novartis Ag | Humaniziranje zajčjih protiteles z uporabo univerzalnega ogrodja protitelesa |
DK3628686T3 (da) | 2008-06-25 | 2021-09-06 | Novartis Ag | Humanisering af kanin-antistoffer under anvendelse af et universelt antistof-framework |
PL2315756T3 (pl) | 2008-07-08 | 2015-02-27 | Incyte Holdings Corp | 1,2,5-oksadiazole jako inhibitory 2,3-dioksygenazy indoloaminy |
EP2322610B1 (en) | 2008-07-16 | 2016-12-14 | Medical and Biological Laboratories Co., Ltd. | Anti-human clcp1 antibody and use thereof |
RU2492871C2 (ru) | 2008-08-01 | 2013-09-20 | АКСИС, Инс. | Терапевтическое или профилактическое средство для лечения остеоартрита |
US8795981B2 (en) | 2008-08-08 | 2014-08-05 | Molecular Devices, Llc | Cell detection |
US8417011B2 (en) | 2008-09-18 | 2013-04-09 | Molecular Devices (New Milton) Ltd. | Colony detection |
EP2172485A1 (en) | 2008-10-01 | 2010-04-07 | Pierre Fabre Medicament | Novel anti CXCR4 antibodies and their use for the treatment of cancer |
EP2346525A4 (en) | 2008-10-02 | 2012-05-09 | Celtaxsys Inc | METHODS OF MODULATION OF NEGATIVE CHIMOTAXIA OF IMMUNE CELLS |
KR20160017117A (ko) | 2008-10-09 | 2016-02-15 | 미네르바 바이오테크놀로지 코포레이션 | 세포내에서 다능성을 유도하기 위한 방법 |
EP2346904B1 (en) | 2008-10-29 | 2017-04-12 | China Synthetic Rubber Corporation | Methods and agents for the diagnosis and treatment of hepatocellular carcinoma |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
WO2010051367A1 (en) | 2008-10-31 | 2010-05-06 | The Trustees Of The University Of Pennsylvania | Simian adenoviruses sadv-43, -45,-48,-49, and -50 and uses thereof |
US8545839B2 (en) | 2008-12-02 | 2013-10-01 | Pierre Fabre Medicament | Anti-c-Met antibody |
US9469691B2 (en) | 2008-12-02 | 2016-10-18 | Pierre Fabre Medicament | Anti-cMET antibody |
AR074439A1 (es) | 2008-12-02 | 2011-01-19 | Pf Medicament | Anticuerpo anti-cmet (receptor c-met) |
BRPI0923157B1 (pt) | 2008-12-19 | 2021-12-28 | University Of Zürich | Anticorpos anti-alfa-sinucleína e seus fragmentos, seus usos e método de preparação, composição compreendendo-os, bem como kit e métodos para o diagnóstico e monitoramento de uma doença sinucleinopática |
US8313915B2 (en) | 2009-01-21 | 2012-11-20 | Gundersen Lutheran Medical Foundation, Inc. | Early detection of canine lyme disease by specific peptides and antibodies |
WO2010085590A1 (en) | 2009-01-23 | 2010-07-29 | Biosynexus Incorporated | Opsonic and protective antibodies specific for lipoteichoic acid gram positive bacteria |
EP2424882A2 (en) | 2009-02-05 | 2012-03-07 | Intercell AG | Peptides protective against e. faecalis, methods and uses relating thereto |
WO2010092176A2 (en) | 2009-02-13 | 2010-08-19 | Intercell Ag | Nontypable haemophilus influenzae antigens |
WO2010096658A1 (en) | 2009-02-19 | 2010-08-26 | The Cleveland Clinic Foundation | Corin as a marker for heart failure |
MX2011009438A (es) | 2009-03-10 | 2012-04-02 | Baylor Res Inst | Anticuerpos anti-cd40 y usos de los mismos. |
CN105884903B (zh) | 2009-03-10 | 2019-12-06 | 贝勒研究院 | 靶向抗原呈递细胞的疫苗 |
JP5883653B2 (ja) | 2009-03-10 | 2016-03-15 | ベイラー リサーチ インスティテュートBaylor Research Institute | 抗原提示細胞ターゲティング抗ウイルスワクチン |
JP5725508B2 (ja) | 2009-03-25 | 2015-05-27 | 国立大学法人東北大学 | Lh型二重特異性抗体 |
MX2011007342A (es) | 2009-04-09 | 2011-07-21 | Daiichi Sankyo Co Ltd | Anticuerpo anti-lectina similar a inmunoglobulina de union a acido sialico-15. |
CA2758322C (en) | 2009-04-10 | 2019-04-02 | Tufts Medical Center, Inc. | Par-1 activation by metalloproteinase-1 (mmp-1) |
DK2419447T3 (en) | 2009-04-17 | 2017-09-25 | Immunas Pharma Inc | ANTIBODIES THAT SPECIFICALLY BIND TO A BETA OLIGOMER AND USE THEREOF |
EP2246364A1 (en) | 2009-04-29 | 2010-11-03 | Pierre Fabre Médicament | Anti CXCR4 antibodies for the treatment of HIV |
CN102458517B (zh) | 2009-04-29 | 2014-07-23 | 阿布维生物技术有限公司 | 自动注射装置 |
EP2270053A1 (en) | 2009-05-11 | 2011-01-05 | U3 Pharma GmbH | Humanized AXL antibodies |
EP2435559A1 (en) | 2009-05-29 | 2012-04-04 | The Trustees Of The University Of Pennsylvania | Simian adenovirus 41 and uses thereof |
EP2260864A1 (en) | 2009-06-10 | 2010-12-15 | University of Melbourne | Therapeutic applications |
TWI513465B (zh) | 2009-06-25 | 2015-12-21 | Regeneron Pharma | 以dll4拮抗劑與化學治療劑治療癌症之方法 |
KR101752515B1 (ko) | 2009-07-24 | 2017-06-29 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Avb5 인테그린과 결부된 질환의 치료 및 예방을 위한 방법 및 조성물 |
CA2768330A1 (en) | 2009-07-28 | 2011-02-03 | F. Hoffmann-La Roche Ag | Non-invasive in vivo optical imaging method |
CA2770237A1 (en) | 2009-08-05 | 2011-02-10 | Nexigen Gmbh | Human hcv-interacting proteins and methods of use |
WO2011024114A1 (en) | 2009-08-25 | 2011-03-03 | Ecole Polytechnique Federale De Lausanne (Epfl) | Targeting extracellular matrix molecules for the treatment of cancer |
TWI412375B (zh) | 2009-08-28 | 2013-10-21 | Roche Glycart Ag | 人類化抗cdcp1抗體 |
JP2013503205A (ja) | 2009-08-31 | 2013-01-31 | アンプリミューン, インコーポレイテッド | 移植拒絶反応を阻害するための方法および組成物 |
AU2010291985B2 (en) | 2009-09-14 | 2016-05-05 | The Regents Of The University Of Colorado | Modulation of yeast-based immunotherapy products and responses |
EP2305285A1 (en) | 2009-09-29 | 2011-04-06 | Julius-Maximilians-Universität Würzburg | Means and methods for treating ischemic conditions |
US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
EP2308897A1 (en) | 2009-10-09 | 2011-04-13 | Pierre Fabre Medicament | Chimeric antibodies specific for CD151 and use thereof in the treatment of cancer |
US9377458B2 (en) | 2009-10-11 | 2016-06-28 | Biogen Ma Inc. | Anti-VLA-4 related assays |
WO2011062112A1 (ja) | 2009-11-18 | 2011-05-26 | 国立大学法人東北大学 | ヒト型化抗egfr抗体可変領域の高機能性変異体 |
EP2332929A1 (en) | 2009-11-25 | 2011-06-15 | ArisGen SA | Orthoester derivatives of crown ethers as carriers for pharmaceutical and diagnostic compositions |
GB0920944D0 (en) | 2009-11-30 | 2010-01-13 | Biotest Ag | Agents for treating disease |
WO2011068870A2 (en) | 2009-12-01 | 2011-06-09 | President And Fellows Of Harvard College | Modulation of nk cell antigen specific effector activity by modulation of cxcr6 (cd186) |
WO2011075578A1 (en) | 2009-12-16 | 2011-06-23 | Philip Bosch | Methods of treating interstitial cystitis |
WO2011088193A2 (en) | 2010-01-13 | 2011-07-21 | University Of Medicine And Dentistry Of New Jersey | Fluorophore chelated lanthanide luminiscent probes with improved quantum efficiency |
US9023997B2 (en) | 2010-01-20 | 2015-05-05 | Merck Sharp & Dohme Corp. | Anti-ILT5 antibodies and ILT5-binding antibody fragments |
WO2011091181A1 (en) | 2010-01-20 | 2011-07-28 | Tolerx, Inc. | Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments |
EP2529751A4 (en) | 2010-01-29 | 2013-07-31 | Axis Inc | INJECTABLE SOLUTION WITH A MEANS FOR THE TREATMENT OF OSTEOARTHRITIS |
JP2012246222A (ja) | 2010-01-29 | 2012-12-13 | Axis Inc | 変形性関節症治療剤または予防剤を製造するための使用 |
KR20120115383A (ko) | 2010-01-29 | 2012-10-17 | 가부시키가이샤 아크시스 | 변형성 관절증 치료 또는 예방용 의약 조성물 및 이의 제조 방법 |
WO2011097301A2 (en) | 2010-02-02 | 2011-08-11 | Abbott Biotechnology Ltd. | METHODS AND COMPOSITIONS FOR PREDICTING RESPONSIVENESS TO TREATMENT WITH TNF-α INHIBITOR |
AU2011213609B2 (en) | 2010-02-08 | 2016-11-03 | Agensys, Inc. | Antibody drug conjugates (ADC) that bind to 161P2F10B proteins |
AU2011217848B8 (en) | 2010-02-18 | 2015-09-24 | The Regents Of The University Of California | Integrin aVB8 neutralizing antibody |
EP2544688B1 (en) | 2010-03-02 | 2016-09-07 | President and Fellows of Harvard College | Methods and compositions for treatment of angelman syndrome |
EP2542571B1 (en) | 2010-03-03 | 2016-05-25 | The University of British Columbia | Oligomer-specific amyloid beta epitope and antibodies |
EP2553449A2 (en) | 2010-03-26 | 2013-02-06 | Westfälische Wilhelms-Universität Münster | Substitute therapy for glucocorticoids |
EP2371863A1 (en) | 2010-03-30 | 2011-10-05 | Pierre Fabre Médicament | Humanized anti CXCR4 antibodies for the treatment of cancer |
MX2012011667A (es) | 2010-04-09 | 2013-03-05 | Critical Care Diagnostics Inc | Anticuerpos st-2 humanos solubles y ensayos. |
PL3202789T3 (pl) | 2010-04-16 | 2020-09-21 | Biogen Ma Inc. | Przeciwciała anty-vla-4 |
WO2011133823A1 (en) | 2010-04-21 | 2011-10-27 | Abbott Biotechnology Ltd. | Wearable automatic injection device for controlled delivery of therapeutic agents |
CN102939538A (zh) | 2010-05-07 | 2013-02-20 | 霍夫曼-拉罗奇有限公司 | 用于离体检测细胞的诊断方法 |
SG10201503904XA (en) | 2010-05-17 | 2015-06-29 | Livtech Inc | Anti-human trop-2 antibody having antitumor activity in vivo |
WO2011146727A1 (en) | 2010-05-19 | 2011-11-24 | Philip Bosch | Methods of treating interstitial cystitis |
US9485812B2 (en) | 2010-07-08 | 2016-11-01 | Honda Motor Co., Ltd. | High frequency heating coil |
KR101842301B1 (ko) | 2010-07-14 | 2018-03-26 | 머크 샤프 앤드 돔 코포레이션 | 항-addl 모노클로날 항체 및 그의 용도 |
CN107090039A (zh) | 2010-07-15 | 2017-08-25 | 亚德赫伦医疗公司 | 靶向于钙粘着蛋白‑11的ec1结构域的人源化抗体及相关组合物和方法 |
DK2598526T3 (en) | 2010-07-29 | 2018-11-19 | Eleven Biotherapeutics Inc | CHEMICAL IL-1 RECEPTOR TYPE-I AGONISTS AND ANTAGONISTS |
RU2607368C2 (ru) | 2010-07-30 | 2017-01-10 | Ац Иммуне С.А. | Безопасные и функциональные гуманизированные антитела |
JP2012034668A (ja) | 2010-08-12 | 2012-02-23 | Tohoku Univ | ヒト型化抗egfr抗体リジン置換可変領域断片及びその利用 |
WO2012027494A1 (en) | 2010-08-24 | 2012-03-01 | Regents Of The University Of Minnesota | Bispecific targeting reagents |
EP2609211A1 (en) | 2010-08-27 | 2013-07-03 | University of Zurich | A novel diagnostic and therapeutic target in inflammatory and/or cardiovascular diseases |
EP2609431B1 (en) | 2010-08-27 | 2017-05-10 | University of Zurich | Method for target and drug validation in inflammatory and/or cardiovascular diseases |
WO2012028697A1 (en) | 2010-09-01 | 2012-03-08 | Eth Zürich, Institute Of Molecular Biology And Biophysics | Affinity purification system based on donor strand complementation |
US20120244141A1 (en) | 2010-09-28 | 2012-09-27 | Boehringer Ingelheim International Gmbh | Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors |
US9675693B2 (en) | 2010-09-30 | 2017-06-13 | Riken | Methods and drugs targeting Eva1 or Ceacam1 gene expression for treatment and diagnosing of glioma |
US8497138B2 (en) | 2010-09-30 | 2013-07-30 | Genetix Limited | Method for cell selection |
MX345092B (es) | 2010-10-11 | 2017-01-17 | Univ Zuerich | Anticuerpos anti-tau humanos,. |
WO2012051111A2 (en) | 2010-10-13 | 2012-04-19 | Janssen Biotech, Inc. | Human oncostatin m antibodies and methods of use |
CA2813796C (en) | 2010-10-18 | 2019-01-15 | Mediapharma S.R.L. | Erbb3 binding antibody |
EP3581206A1 (en) | 2010-10-22 | 2019-12-18 | Seattle Genetics, Inc. | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the p13k-akt mtor pathway |
UY33679A (es) | 2010-10-22 | 2012-03-30 | Esbatech | Anticuerpos estables y solubles |
RS60565B1 (sr) | 2010-10-25 | 2020-08-31 | Biogen Ma Inc | Postupci za određivanje razlika u aktivnosti alfa-4 integrina putem uspostavljanja korelacije sa razlikama u nivoima svcam i/ili smadcam |
JP2014504147A (ja) | 2010-10-27 | 2014-02-20 | ピエール、ファーブル、メディカマン | Hivの治療用抗体 |
MX344200B (es) | 2010-10-29 | 2016-12-08 | Daiichi Sankyo Co Ltd | Novedoso anticuerpo anti-dr5. |
EP2640425A2 (en) | 2010-11-18 | 2013-09-25 | Beth Israel Deaconess Medical Center, Inc. | Methods of treating obesity by inhibiting nicotinamide n-methyl transferase (nnmt) |
SG191716A1 (en) | 2010-11-19 | 2013-08-30 | Toshio Imai | Neutralizing anti-ccl20 antibodies |
WO2012071318A2 (en) | 2010-11-23 | 2012-05-31 | The Trustees Of The University Of Pennsylvania | Subfamily e simian adenoviruses a1321, a1325, a1295, a1309, a1316 and a1322 and uses thereof |
WO2012080518A1 (en) | 2010-12-17 | 2012-06-21 | Neurimmune Holding Ag | Human anti-sod1 antibodies |
EP2659910B1 (en) | 2010-12-27 | 2016-11-09 | National University Corporation Nagoya University | Screening method for a compound capable of suppressing receptor tyrosine kinase-mediated pro-survival signaling in a cancer cell |
WO2012095412A1 (en) | 2011-01-10 | 2012-07-19 | Ct Atlantic Ltd. | Combination therapy including tumor associated antigen binding antibodies |
EP3252076B1 (en) | 2011-01-14 | 2019-09-04 | The Regents Of The University Of California | Diagnostic use of antibodies against ror-1 protein |
JP6478214B2 (ja) | 2011-01-24 | 2019-03-06 | アッヴィ バイオテクノロジー リミテッド | オーバーモールド把持面を有する自動注射器 |
WO2012104824A1 (en) | 2011-02-04 | 2012-08-09 | Ecole polytechnique fédérale de Lausanne (EPFL) | Therapeutic antibodies targeting app-c99 |
WO2012107589A1 (en) | 2011-02-11 | 2012-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment and prevention of hcv infections |
WO2012110843A1 (en) | 2011-02-18 | 2012-08-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for promoting fibrinolysis and thrombolysis |
WO2012113775A1 (en) | 2011-02-21 | 2012-08-30 | University Of Zurich | Ankyrin g and modulators thereof for the treatment of neurodegenerative disorders |
WO2012120004A1 (en) | 2011-03-07 | 2012-09-13 | F. Hoffmann-La Roche Ag | In vivo selection of therapeutically active antibodies |
WO2012119999A1 (en) | 2011-03-07 | 2012-09-13 | F. Hoffmann-La Roche Ag | Means and methods for in vivo testing of therapeutic antibodies |
US10139420B2 (en) | 2011-03-09 | 2018-11-27 | ISNERM (Institut National de la Sante et de la Recherche Medicale) | Methods for treating vaso-occlusive crisis using non-modified annexin V |
WO2012125680A1 (en) | 2011-03-16 | 2012-09-20 | Novartis Ag | Methods of treating vasculitis using an il-17 binding molecule |
EP2686417B1 (de) | 2011-03-17 | 2016-06-08 | Miltenyi Biotec GmbH | Tcralpha/beta-depletierte zellpräparationen |
WO2012126013A2 (en) | 2011-03-17 | 2012-09-20 | Minerva Biotechnologies Corporation | Method for making pluripotent stem cells |
US20120301465A1 (en) | 2011-03-25 | 2012-11-29 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Compositions and methods to immunize against hepatitis c virus |
TW201249867A (en) | 2011-04-01 | 2012-12-16 | Astellas Pharma Inc | Novel anti-human il-23 receptor antibody |
CN107096098A (zh) | 2011-04-21 | 2017-08-29 | 艾伯维公司 | 可佩戴式自动注射装置 |
CN103687945B (zh) | 2011-04-25 | 2016-10-12 | 第一三共株式会社 | 抗-b7-h3抗体 |
LT2704742T (lt) | 2011-05-02 | 2017-10-25 | Millennium Pharmaceuticals, Inc. | Anti-alfa4beta7 antikūno kompozicija |
UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
WO2012154889A1 (en) | 2011-05-09 | 2012-11-15 | The Cleveland Clinic Foundation | Serum s100b and uses thereof |
WO2012163848A1 (en) | 2011-05-27 | 2012-12-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of crohn's disease |
EP2530088A1 (en) | 2011-05-30 | 2012-12-05 | Klinikum rechts der Isar der Technischen Universität München | Means and methods for diagnosing and treating multiple sclerosis |
EP2714743A1 (en) | 2011-06-03 | 2014-04-09 | CT Atlantic Ltd. | Magea3 binding antibodies |
EP2714742A1 (en) | 2011-06-03 | 2014-04-09 | CT Atlantic Ltd. | Magea3 binding antibodies |
WO2012170071A1 (en) | 2011-06-06 | 2012-12-13 | Elan Pharmaceuticas, Inc | Mcam antagonists and methods of treatment |
WO2012172449A1 (en) | 2011-06-13 | 2012-12-20 | Pfizer Inc. | Lactams as beta secretase inhibitors |
US20140120555A1 (en) | 2011-06-20 | 2014-05-01 | Pierre Fabre Medicament | Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer |
LT2723379T (lt) | 2011-06-23 | 2018-10-25 | Biogen International Neuroscience Gmbh | Anti-alfa sinukleiną rišančios molekulės |
DE202011103324U1 (de) | 2011-07-12 | 2012-01-02 | Nekonal S.A.R.L. | Therapeutische anti-TIRC7 Antikörper für die Verwendung in Immun und anderen Krankheiten |
GB201112056D0 (en) | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
US20140308275A1 (en) | 2011-07-27 | 2014-10-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale | Methods for diagnosing and treating myhre syndrome |
EP2743348B1 (en) | 2011-08-11 | 2018-01-10 | Astellas Pharma Inc. | Novel anti-human ngf antibody |
WO2013024022A1 (en) | 2011-08-12 | 2013-02-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
US20140242085A1 (en) | 2011-08-12 | 2014-08-28 | Medical & Biological Laboratories Co., Ltd. | Methods and composition for testing, preventing, and treating aspergillus fumigatus infection |
GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
KR20210099167A (ko) | 2011-09-19 | 2021-08-11 | 악손 뉴로사이언스 에스이 | 알쯔하이머병의 타우 매개된 병리학의 단백질 기재 요법 및 진단 |
GB2495115A (en) * | 2011-09-29 | 2013-04-03 | Oxford Plastic Sys Ltd | Base for supporting temporary fence panels or posts. |
TW201329105A (zh) | 2011-10-04 | 2013-07-16 | Thr Trustees Of Columbia University In The City Of New York | 人類notch1引誘物 |
WO2013050441A1 (en) | 2011-10-05 | 2013-04-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for inhibiting or preventing platelet aggregation |
EP2764118A1 (en) | 2011-10-05 | 2014-08-13 | University of Bremen | Wnt4 and med12 for use in the diagnosis and treatment of tumor diseases |
WO2013054320A1 (en) | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) |
WO2013055911A1 (en) | 2011-10-14 | 2013-04-18 | Dana-Farber Cancer Institute, Inc. | Znf365/zfp365 biomarker predictive of anti-cancer response |
CN109456932A (zh) | 2011-10-17 | 2019-03-12 | 米纳瓦生物技术公司 | 用于干细胞增殖和诱导的培养基 |
WO2013057313A1 (en) | 2011-10-20 | 2013-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the detection and the treatment of cardiac remodeling |
EP2589609A1 (en) | 2011-11-03 | 2013-05-08 | Pierre Fabre Medicament | Antigen binding protein and its use as addressing product for the treatment of cancer |
US9427464B2 (en) | 2011-11-22 | 2016-08-30 | Chiome Bioscience Inc. | Anti-human TROP-2 antibody having an antitumor activity in vivo |
AU2012342482A1 (en) | 2011-11-22 | 2014-05-22 | Cnrs (Centre National De La Recherche Scientifique) | Methods and pharmaceutical compositions for reducing airway hyperresponse |
ES2638649T3 (es) | 2011-11-28 | 2017-10-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Composición farmacéutica para su uso en el tratamiento de disfunciones asociadas al envejecimiento |
EP2602621A1 (en) | 2011-12-08 | 2013-06-12 | Julius-Maximilians-Universität Würzburg | LASP-1, a novel urinary marker for transitional cell carcinoma detection |
WO2013088363A1 (en) * | 2011-12-13 | 2013-06-20 | Nordic Nanovector As | Chimeric therapeutic anti - cd37 antibodie hh1 |
FR2984750B1 (fr) | 2011-12-23 | 2014-01-10 | Lfb Biotechnologies | Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii |
WO2013093122A2 (en) | 2011-12-23 | 2013-06-27 | Phenoquest Ag | Antibodies for the treatment and diagnosis of affective and anxiety disorders |
AU2013206788B2 (en) | 2011-12-28 | 2017-11-30 | Immunoqure Ag | Method of providing monoclonal auto-antibodies with desired specificity |
WO2013098813A1 (en) | 2012-01-01 | 2013-07-04 | Qbi Enterprises Ltd. | Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents |
EP2812702B1 (en) | 2012-02-10 | 2019-04-17 | Seattle Genetics, Inc. | Diagnosis and management of CD30-expressing cancers |
US10160808B2 (en) | 2012-02-16 | 2018-12-25 | Santarus, Inc. | Anti-VLA1 (CD49A) antibody pharmaceutical compositions |
BR112014020666A2 (pt) | 2012-02-23 | 2018-09-25 | U3 Pharma Gmbh | usos de um inibidor de her3 |
PT2821416T (pt) | 2012-02-28 | 2018-12-14 | Astellas Pharma Inc | Anticorpo de recetor il-23 anti- humano inovador |
UA121844C2 (uk) | 2012-03-15 | 2020-08-10 | Янссен Байотек, Інк. | Людське антитіло до cd27, спосіб його одержання та застосування |
TR201909801T4 (tr) | 2012-03-20 | 2019-07-22 | Biogen Ma Inc | JCV nötrleştirici antikorlar. |
US20150125470A1 (en) | 2012-03-30 | 2015-05-07 | Daiichi Sankyo Company, Limited | Novel anti-siglec-15 antibody |
KR20150003170A (ko) | 2012-03-30 | 2015-01-08 | 다이이찌 산쿄 가부시키가이샤 | CDR 개변 항 Siglec-15 항체 |
CN103382223B (zh) | 2012-04-01 | 2015-06-10 | 上海益杰生物技术有限公司 | 针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽 |
ES2702278T3 (es) | 2012-04-01 | 2019-02-28 | Technion Res & Dev Foundation | Péptidos de inductor de metaloproteinasa de matriz extracelular (emmprin) y anticuerpos de unión |
MX2014011849A (es) | 2012-04-02 | 2015-04-08 | Gundersen Lutheran Health System Inc | Reactivos, procedimientos y kits para la clasificación del cáncer. |
KR102115143B1 (ko) | 2012-04-09 | 2020-05-28 | 다이이찌 산쿄 가부시키가이샤 | 항 fgfr2 항체 |
JP5897205B2 (ja) | 2012-04-27 | 2016-03-30 | 第一三共株式会社 | 抗robo4抗体 |
US9062120B2 (en) | 2012-05-02 | 2015-06-23 | Janssen Biotech, Inc. | Binding proteins having tethered light chains |
JP6263117B2 (ja) | 2012-05-11 | 2018-01-17 | 公益財団法人微生物化学研究会 | 抗cxadr抗体 |
BR112014028306A2 (pt) | 2012-05-15 | 2018-04-17 | Morphotek, Inc. | métodos para tratamento de câncer gástrico. |
MX358019B (es) | 2012-05-18 | 2018-08-02 | Univ Pennsylvania | Adenovirus de simio de la subfamilia e a1302, a1320, a1331 y a1337 y sus usos. |
EP2852679A1 (en) | 2012-05-22 | 2015-04-01 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for diagnosing and treating focal segmental glomerulosclerosis |
JP5868549B2 (ja) | 2012-05-24 | 2016-02-24 | マウントゲイト グループ リミテッド | 狂犬病感染の予防および治療に関する組成物および方法 |
PL2872171T3 (pl) | 2012-07-13 | 2021-07-12 | The Trustees Of The University Of Pennsylvania | Kontrola toksyczności wobec aktywności przeciwnowotworowej CAR |
WO2014013005A1 (en) | 2012-07-18 | 2014-01-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for preventing and treating chronic kidney disease (ckd) |
EP3539563A1 (en) | 2012-07-19 | 2019-09-18 | Redwood Bioscience, Inc. | Antibody specific for cd22 and methods of use thereof |
US9840552B2 (en) | 2012-07-30 | 2017-12-12 | National University Corporation Nagoya University | Monoclonal antibody against human midkine |
MY181648A (en) | 2012-08-24 | 2020-12-30 | Univ California | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis |
TWI660972B (zh) | 2012-09-10 | 2019-06-01 | 愛爾蘭商尼歐托普生物科學公司 | 抗mcam抗體及相關使用方法 |
SG11201501924UA (en) | 2012-09-13 | 2015-05-28 | Chugai Pharmaceutical Co Ltd | Gene knock-in non-human animal |
EP2711016A1 (en) | 2012-09-21 | 2014-03-26 | Covagen AG | Novel IL-17A binding molecules and medical uses thereof |
SI2905335T1 (en) | 2012-10-03 | 2018-04-30 | Chiome Bioscience Inc. | PROTITEL AGAINST HUMANEMU DLK-1 WITH PROTITUM ACTIVITY AND VIVO |
EP3677310A1 (en) | 2012-10-08 | 2020-07-08 | St. Jude Children's Research Hospital | Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis |
PT3342785T (pt) | 2012-10-11 | 2020-02-25 | Daiichi Sankyo Co Ltd | Ligantes para conjugados de anticorpo-fármaco |
DE102012020496A1 (de) | 2012-10-18 | 2014-04-24 | Charité - Universitätsmedizin Berlin | Biomarker zur Diagnostik und Behandlung von Neurofibromatose Typ 1 |
EP2910573B1 (en) | 2012-10-19 | 2020-02-19 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate produced by binding through linker having hydrophilic structure |
EP2911681A1 (en) | 2012-10-26 | 2015-09-02 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis |
WO2014068079A1 (en) | 2012-11-01 | 2014-05-08 | Max-Delbrück-Centrum für Molekulare Medizin | An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases |
PL2914630T3 (pl) | 2012-11-05 | 2021-09-06 | Pierre Fabre Médicament | Nowe białka wiążące antygen i ich zastosowanie jako produktu ukierunkowanego do leczenia raka |
EP2917347B1 (en) | 2012-11-08 | 2019-01-02 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods and pharmaceutical compositions for the treatment of bone metastases |
TW201438736A (zh) | 2012-11-14 | 2014-10-16 | Regeneron Pharma | 以dll4拮抗劑治療卵巢癌之方法 |
WO2014093396A1 (en) | 2012-12-10 | 2014-06-19 | Biogen Idec Ma Inc. | Anti-blood dendritic cell antigen 2 antibodies and uses thereof |
EP3514175A1 (fr) | 2012-12-17 | 2019-07-24 | Laboratoire Français du Fractionnement et des Biotechnologies | Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes |
US10024844B2 (en) | 2012-12-20 | 2018-07-17 | Hospital For Special Surgery | Identification of an inhibitor of iRhom1 or an inhibitor of iRhom2 |
CA2896066C (en) | 2012-12-21 | 2022-07-12 | Biogen Ma Inc. | Human anti-tau antibodies |
JP6407165B2 (ja) | 2012-12-31 | 2018-10-17 | ニューリミューン ホールディング エイジー | ポリオーマウイルス関連疾患の治療および防止のための組換えヒト抗体 |
EP2752426A1 (en) | 2013-01-03 | 2014-07-09 | Covagen AG | Human serum albumin binding compounds and fusion proteins thereof |
CA2897914A1 (en) | 2013-01-28 | 2014-07-31 | Evec Inc. | Humanized anti-hmgb1 antibody or antigen-binding fragment thereof |
JP2016508606A (ja) | 2013-02-01 | 2016-03-22 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | トリプルネガティブ乳ガンにおける転移を予測及び予防するための方法 |
US9932396B2 (en) | 2013-02-08 | 2018-04-03 | Medical & Biological Laboratories Co., Ltd. | Antibody against human NRG1 protein |
EP2956478A1 (en) | 2013-02-15 | 2015-12-23 | ESBATech - a Novartis Company LLC | Acceptor framework for cdr grafting |
EP2958939A1 (en) | 2013-02-20 | 2015-12-30 | ESBATech - a Novartis Company LLC | Acceptor framework for cdr grafting |
FR3004184B1 (fr) | 2013-02-26 | 2016-03-18 | Agronomique Inst Nat Rech | Anticorps anti-gluten desamide et utilisations. |
EP3339327A3 (en) | 2013-02-28 | 2018-09-19 | National Cancer Center | Antibody against insoluble fibrin |
WO2014136910A1 (ja) | 2013-03-08 | 2014-09-12 | 国立大学法人大阪大学 | ペリオスチンのExon-21部位によりコードされるペプチドに対する抗体及び該抗体を含む炎症関連疾患の予防又は治療用医薬組成物 |
US10023608B1 (en) | 2013-03-13 | 2018-07-17 | Amgen Inc. | Protein purification methods to remove impurities |
MX2015012404A (es) | 2013-03-13 | 2016-02-03 | Eleven Biotherapeutics Inc | Formulaciones de citoquinas quimericas para suministro ocular. |
WO2014151917A1 (en) | 2013-03-14 | 2014-09-25 | Ffe Therapeutics Llc | Compositions and methods for treating angiogenesis-related disorders |
US9302005B2 (en) | 2013-03-14 | 2016-04-05 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
WO2014143739A2 (en) | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Anti-alpha v beta 6 antibodies and uses thereof |
WO2014144466A1 (en) | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Anti-alpha v beta 6 antibodies and uses thereof |
EP2970475A1 (en) | 2013-03-15 | 2016-01-20 | Biogen MA Inc. | Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies |
CN105229032A (zh) | 2013-03-18 | 2016-01-06 | 比奥塞罗克斯产品公司 | 人源化抗cd134(ox40)抗体及其应用 |
EP2981554B1 (en) | 2013-04-01 | 2020-07-29 | The Regents of The University of California | Methods and compositions for treating and preventing disease associated with avb8 integrin |
WO2014174596A1 (ja) | 2013-04-23 | 2014-10-30 | 株式会社医学生物学研究所 | ヘパリン結合上皮増殖因子様増殖因子に対する機能性モノクローナル抗体 |
US9717648B2 (en) | 2013-04-24 | 2017-08-01 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
CN104140974B (zh) | 2013-05-08 | 2017-09-29 | 科济生物医药(上海)有限公司 | 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞 |
WO2014205374A1 (en) | 2013-06-20 | 2014-12-24 | The Trustees Of The University Of Pennsylvania | Methods for diagnosing pancreatic cancer |
CA2917112C (en) | 2013-07-03 | 2022-07-05 | Immunoqure Ag | Human anti-ifn-alpha antibodies |
WO2015001082A1 (en) | 2013-07-05 | 2015-01-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof |
EP3016683B1 (en) | 2013-07-05 | 2020-06-24 | University of Washington through its Center for Commercialization | Soluble mic neutralizing monoclonal antibody for treating cancer |
TR201906969T4 (tr) | 2013-08-09 | 2019-06-21 | Astellas Pharma Inc | Yeni anti-insan tslp reseptör antikoru. |
US20160216262A1 (en) | 2013-09-12 | 2016-07-28 | Institut National De La Sante Et De La Recherche Medicale | Method for In Vitro Quantifying Allo-Antibodies, Auto-Antibodies and/or Therapeutic Antibodies |
US10406215B2 (en) | 2013-09-20 | 2019-09-10 | Westfälische Wilhelms-Universität Münster | Cell-penetrating bacterial E3-ubiqitin-ligases for use in immunotherapy |
US9957295B2 (en) | 2013-09-24 | 2018-05-01 | The Feinstein Institute For Medical Research | Peptides inhibiting cold-inducible RNA binding protein activity |
WO2015048531A1 (en) | 2013-09-26 | 2015-04-02 | Beth Israel Deaconess Medical Center, Inc. | Inhibition of sgk1 in the treatment of heart conditions |
EP3061818B1 (en) | 2013-09-30 | 2020-12-16 | Daiichi Sankyo Company, Limited | Anti-lps o11 antibody |
WO2015050663A1 (en) | 2013-10-01 | 2015-04-09 | Mayo Foundation For Medical Education And Research | Methods for treating cancer in patients with elevated levels of bim |
KR20160066024A (ko) | 2013-10-08 | 2016-06-09 | 다이이찌 산쿄 가부시키가이샤 | 항 fgfr2 항체와 타제의 조합 |
LT3065774T (lt) | 2013-11-06 | 2021-09-10 | Janssen Biotech, Inc. | Anti-ccl17 antikūnai |
EP3070167A4 (en) | 2013-11-06 | 2017-06-07 | Osaka University | Antibody having broad neutralizing activity in group 1 influenza a virus |
EP3068419A1 (en) | 2013-11-15 | 2016-09-21 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical compositions for the treatment of pancreatic cancers |
WO2015082446A1 (en) | 2013-12-02 | 2015-06-11 | F. Hoffmann-La Roche Ag | Treatment of cancer using an anti-cdcp1 antibody and a taxane |
CN109535254B (zh) | 2013-12-24 | 2022-06-24 | 安斯泰来制药株式会社 | 抗人bdca-2抗体、其生产方法、多核苷酸、表达载体、宿主细胞及医药组合物 |
KR102237803B1 (ko) | 2013-12-25 | 2021-04-09 | 다이이찌 산쿄 가부시키가이샤 | 항 trop2 항체-약물 컨쥬게이트 |
ES2902835T3 (es) | 2014-01-09 | 2022-03-30 | Hadasit Med Res Service | Composiciones celulares mejoradas y métodos para la terapia contra el cáncer |
CA2936833A1 (en) | 2014-01-13 | 2015-07-16 | Baylor Research Institute | Novel vaccines against hpv and hpv-related diseases |
CN104774264B (zh) | 2014-01-15 | 2018-09-14 | 上海易乐生物技术有限公司 | 抗人proBDNF单克隆抗体及其在疼痛中的作用 |
PT3101032T (pt) | 2014-01-31 | 2019-04-03 | Daiichi Sankyo Co Ltd | Onjugado de anticorpo anti-her2-fármaco |
WO2015124570A1 (en) | 2014-02-18 | 2015-08-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of influenza a virus infection |
EP3108255B1 (en) | 2014-02-18 | 2020-08-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of diseases mediated by the nrp-1/obr complex signaling pathway |
EP3415160B1 (en) | 2014-03-04 | 2021-08-18 | Klinikum der Universität München | Polypeptides derived from enterococcus and their use for vaccination and the generation of therapeutic antibodies |
WO2015140351A1 (en) | 2014-03-21 | 2015-09-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for enhancing myelination |
EP3122768A2 (en) | 2014-03-27 | 2017-02-01 | Yeda Research and Development Co. Ltd. | T-cell receptor cdr3 peptides and antibodies |
PT3129063T (pt) | 2014-04-10 | 2021-04-01 | Daiichi Sankyo Europe Gmbh | Conjugado anticorpo anti-her3-fármaco |
US20170037476A1 (en) | 2014-04-15 | 2017-02-09 | Helmholtz Zentrum München-Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Differential diagnosis of eczema and psoriasis |
US11624093B2 (en) | 2014-04-24 | 2023-04-11 | Dana-Farber Cancer Institute, Inc. | Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response |
SI3134125T1 (sl) | 2014-04-25 | 2020-02-28 | Pierre Fabre Medicament | Konjugat zdravila s protitelesom in uporaba le-tega za zdravljenje raka |
PT3134438T (pt) | 2014-04-25 | 2020-12-31 | Pf Medicament | Anticorpo igf-1r e sua utilização como veículo de endereçamento para o tratamento de cancro |
CN106456800B (zh) | 2014-04-25 | 2018-05-01 | 皮埃尔法布雷医药公司 | Igf-1r抗体-药物-缀合物和其用于治疗癌症的用途 |
CA2946262C (en) | 2014-04-27 | 2022-07-26 | Ccam Biotherapeutics Ltd. | Humanized antibodies against ceacam1 |
US11427647B2 (en) | 2014-04-27 | 2022-08-30 | Famewave Ltd. | Polynucleotides encoding humanized antibodies against CEACAM1 |
US10302653B2 (en) | 2014-05-22 | 2019-05-28 | Mayo Foundation For Medical Education And Research | Distinguishing antagonistic and agonistic anti B7-H1 antibodies |
TWI713453B (zh) | 2014-06-23 | 2020-12-21 | 美商健生生物科技公司 | 干擾素α及ω抗體拮抗劑 |
WO2015200790A2 (en) | 2014-06-26 | 2015-12-30 | Yale University | Compositions and methods to regulate renalase in the treatment of diseases and disorders |
CN112979828A (zh) | 2014-07-17 | 2021-06-18 | 恺兴生命科技(上海)有限公司 | 靶向cld18a2的t淋巴细胞及其制备方法和应用 |
US20170227541A1 (en) | 2014-07-17 | 2017-08-10 | The Trustees Of The University Of Pennsylvania | Methods for using exosomes to monitor transplanted organ status |
WO2016014148A1 (en) | 2014-07-23 | 2016-01-28 | Mayo Foundation For Medical Education And Research | Targeting dna-pkcs and b7-h1 to treat cancer |
JP2017522886A (ja) | 2014-07-29 | 2017-08-17 | ニューリミューン ホールディング エイジー | ヒト由来抗ハンチンチン(htt)抗体及びその使用 |
CN108064248B (zh) | 2014-09-30 | 2022-03-15 | 生物控股有限公司 | 人源抗二肽重复(dpr)抗体 |
CA2963470A1 (en) | 2014-10-03 | 2016-04-07 | Massachusetts Institute Of Technology | Antibodies that bind ebola glycoprotein and uses thereof |
WO2016057367A1 (en) | 2014-10-06 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response |
AU2015328163B2 (en) | 2014-10-09 | 2020-10-15 | Dana-Farber Cancer Institute, Inc. | Multiple-variable IL-2 dose regimen for treating immune disorders |
ES2832802T3 (es) | 2014-11-21 | 2021-06-11 | Univ Maryland | Sistemas de administración dirigida del particulado específico de una estructura |
US20170319661A1 (en) | 2014-12-03 | 2017-11-09 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and Pharmaceutical Compositions Using Orexins (OXA, OXB) for the Treatment of Prostate Cancers |
WO2016128523A1 (en) | 2015-02-12 | 2016-08-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease |
EP3265825A4 (en) | 2015-03-06 | 2018-08-08 | Dana-Farber Cancer Institute, Inc. | Pd-l2 biomarkers predictive of pd-1 pathway inhibitor responses in esophagogastric cancers |
EP3067062A1 (en) | 2015-03-13 | 2016-09-14 | Ipsen Pharma S.A.S. | Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament |
EP3271397B1 (en) | 2015-03-18 | 2021-03-03 | The Johns Hopkins University | Inhibitory monoclonal antibody targeting potassium channel kcnk9 |
US10426818B2 (en) | 2015-03-24 | 2019-10-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Method and pharmaceutical composition for use in the treatment of diabetes |
WO2016156557A1 (en) | 2015-04-03 | 2016-10-06 | Alienor Farma | Monoclonal antibody to human line-1 orf2 protein and method for early detection of transforming cells in pre-neoplastic tissues of a human subject |
EP3283108B1 (en) | 2015-04-13 | 2020-10-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treatment of haemorrhagic diseases |
EP3286221A1 (en) | 2015-04-22 | 2018-02-28 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical compositions for the treatment of th17 mediated diseases |
EA201792662A1 (ru) | 2015-06-01 | 2018-04-30 | Медиджин Иммьюнотерапиз Гмбх | Специфические антитела к т-клеточному рецептору |
JP2018517711A (ja) | 2015-06-01 | 2018-07-05 | メディジーン イミュノテラピーズ ゲーエムベーハー | 細胞表面タンパク質に対する抗体を作製する方法 |
AU2016273213B2 (en) | 2015-06-01 | 2019-03-14 | Medigene Immunotherapies Gmbh | T cell receptor library |
US11384104B2 (en) | 2015-06-19 | 2022-07-12 | Centurion Biopharma Corporation | Delivery systems for controlled drug release |
CN108139375A (zh) | 2015-06-26 | 2018-06-08 | 贝斯以色列女执事医疗中心股份有限公司 | 靶向髓样衍生的抑制细胞中的四跨膜蛋白33(tspan33)的癌症疗法 |
IL290959B2 (en) | 2015-06-29 | 2023-04-01 | Daiichi Sankyo Co Ltd | Preparations containing antibody-drug conjugates and methods for their production |
CN114605549A (zh) | 2015-08-05 | 2022-06-10 | 詹森生物科技公司 | 抗cd154抗体及其使用方法 |
WO2017046335A1 (en) | 2015-09-18 | 2017-03-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | T cell receptors (tcr) and uses thereof for the diagnosis and treatment of diabetes |
EP3353196B1 (en) | 2015-09-22 | 2022-12-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Polypeptides capable of inhibiting the binding between leptin and neuropilin-1 |
MX2018003594A (es) | 2015-09-24 | 2018-06-15 | Daiichi Sankyo Co Ltd | Anticuerpo anti-garp. |
US10544229B2 (en) | 2015-09-30 | 2020-01-28 | Janssen Biotech, Inc. | Agonistic antibodies specifically binding CD40 and methods of use |
CN108138171B (zh) | 2015-10-08 | 2022-05-13 | 国立大学法人名古屋大学 | 表达嵌合抗原受体的基因修饰t细胞的制备方法 |
EP3362093A4 (en) | 2015-10-13 | 2019-05-08 | Technion Research & Development Foundation Limited | MONOCLONAL ANTIBODIES NEUTRALIZING HEPARANASE |
US20180305458A1 (en) | 2015-10-16 | 2018-10-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases |
MX2018005070A (es) | 2015-10-26 | 2018-09-06 | Pf Medicament | Composición para el tratamiento de cáncer con expresión del igf-1r. |
WO2017075045A2 (en) | 2015-10-30 | 2017-05-04 | Mayo Foundation For Medical Education And Research | Antibodies to b7-h1 |
ITUB20155272A1 (it) | 2015-11-02 | 2017-05-02 | Scuola Normale Superiore | Intracellular antibody |
CN108350077A (zh) | 2015-11-03 | 2018-07-31 | 糖模拟物有限公司 | 产生单克隆抗体、造血干细胞的方法和组合物以及利用所述抗体和造血干细胞的方法 |
EP4046655A1 (en) | 2015-11-03 | 2022-08-24 | Janssen Biotech, Inc. | Antibodies specifically binding pd-1 and their uses |
ITUB20155097A1 (it) | 2015-11-05 | 2017-05-05 | Biouniversa Srl | Anticorpi umanizzati anti-BAG3 |
WO2017097889A1 (en) | 2015-12-10 | 2017-06-15 | Katholieke Universiteit Leuven | Anti adamts13 antibodies and their use for treatment or prevention of haemorrhagic disorders due to ventricular assist device |
US20180355043A1 (en) | 2015-12-17 | 2018-12-13 | Janssen Biotech, Inc. | Antibodies Specifically Binding HLA-DR and Their Uses |
GB201522394D0 (en) | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibodies |
JP6697562B2 (ja) | 2015-12-23 | 2020-05-20 | メディジーン イミュノテラピーズ ゲーエムベーハー | 樹状細胞組成物 |
KR102428254B1 (ko) | 2015-12-31 | 2022-08-03 | 프로가스트린 에 캔서스 에스.에이 알.엘. | 난소암의 검출 및 치료를 위한 조성물 및 방법 |
CA3009785A1 (en) | 2015-12-31 | 2017-07-06 | Progastrine Et Cancers S.A R.L. | Compositions and methods for detecting and treating esophageal cancer |
CN108700588A (zh) | 2015-12-31 | 2018-10-23 | 普莱戈斯瑞恩癌症有限责任公司 | 用于检测和治疗胃癌的组合物和方法 |
EP3202788A1 (en) | 2016-02-05 | 2017-08-09 | MediaPharma S.r.l. | Endosialin-binding antibody |
EP3205663A1 (en) | 2016-02-15 | 2017-08-16 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Means and methods for inhibiting gene expression |
WO2017140684A2 (en) | 2016-02-15 | 2017-08-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction |
CA3015619A1 (en) | 2016-03-01 | 2017-09-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Antibodies specific to human poliovirus receptor (pvr) |
WO2017153432A1 (en) | 2016-03-07 | 2017-09-14 | Pierre Fabre Medicament | A new universal method to capture and analyze adcs for characterization of drug distribution and the drug-to-antibody ratio in biological samples |
US11921116B2 (en) | 2016-03-09 | 2024-03-05 | Memorial Sloan Kettering Cancer Center | Enigma and CDH18 as companion diagnostics for CDK4 inhibitors |
ES2944259T3 (es) | 2016-03-15 | 2023-06-20 | Inst Nat Sante Rech Med | Procedimiento para activar la respuesta antitumoral de linfocitos T CD8+ de un paciente afectado con un cáncer |
WO2017158396A1 (en) | 2016-03-16 | 2017-09-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Cytidine deaminase inhibitors for the treatment of pancreatic cancer |
WO2017162604A1 (en) | 2016-03-21 | 2017-09-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosis and treatment of solar lentigo |
JP7080213B2 (ja) | 2016-03-23 | 2022-06-03 | スーチョウ トランセンタ セラピューティクス カンパニー,リミテッド | 新規抗pd-l1抗体 |
JP7034084B2 (ja) | 2016-03-28 | 2022-03-11 | インサイト・コーポレイション | Tam阻害剤としてのピロロトリアジン化合物 |
ITUA20162242A1 (it) | 2016-04-01 | 2017-10-01 | St Biochimico Italiano Giovanni Lorenzini Spa | Un nuovo anticorpo anti-erbb2 |
EP3445785B1 (en) | 2016-04-18 | 2022-06-22 | Faron Pharmaceuticals OY | Humanized anti clever-1 antibodies and their use |
WO2017191100A1 (en) | 2016-05-03 | 2017-11-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of tissue lesions |
IL300591A (en) | 2016-05-11 | 2023-04-01 | Amgen Inc | Direct selection of cells expressing high levels of heteromeric proteins using intergenic glutamine synthetase complementation vectors |
US20190290756A1 (en) | 2016-05-20 | 2019-09-26 | Christoph Karl | Pharmaceutical compositions with anti-rankl antibodies, calcium and vitamin d |
EP3464357A1 (en) | 2016-05-24 | 2019-04-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections |
WO2017202814A1 (en) | 2016-05-24 | 2017-11-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of neuropathological disorders characterized by a loss of cortical neurons |
US12048718B2 (en) | 2016-06-07 | 2024-07-30 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Geminschaft | Chimeric antigen receptor and CAR-T cells that bind BCMA |
GB201610198D0 (en) | 2016-06-10 | 2016-07-27 | Ucb Biopharma Sprl | Anti-ige antibodies |
JP2019522800A (ja) | 2016-07-06 | 2019-08-15 | プロセナ バイオサイエンシーズ リミテッド | 総及びS129リン酸化α−シヌクレインの検出アッセイ |
JP2018035137A (ja) | 2016-07-13 | 2018-03-08 | マブイミューン ダイアグノスティックス エイジーMabimmune Diagnostics Ag | 新規な抗線維芽細胞活性化タンパク質(fap)結合薬剤およびその使用 |
US20190330318A1 (en) | 2016-07-25 | 2019-10-31 | Biogen Ma Inc. | Anti-hspa5 (grp78) antibodies and uses thereof |
EP3491387A1 (en) | 2016-07-28 | 2019-06-05 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods of treatement of cancer disease by targetting tumor associated macrophage |
US20180044430A1 (en) | 2016-08-12 | 2018-02-15 | Janssen Biotech, Inc. | FC Engineered Anti-TNFR Superfamily Member Antibodies Having Enhanced Atonistic Activity and Methods of Using Them |
US10669344B2 (en) | 2016-08-12 | 2020-06-02 | Janssen Biotech, Inc. | Engineered antibodies and other Fc-domain containing molecules with enhanced agonism and effector functions |
EP3515559A4 (en) | 2016-09-20 | 2020-07-15 | Dana-Farber Cancer Institute, Inc. | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION, ASSESSMENT, PREVENTION AND TREATMENT OF AML USING USP10 BIOMARKERS AND MODULATORS |
EP3524267A4 (en) | 2016-10-07 | 2020-06-10 | Daiichi Sankyo Company, Limited | THERAPY FOR DRUG-RESISTANT CANCER BY ADMINISTERING ANTI-HER2 ANTIBODIES / DRUG CONJUGATE |
JPWO2018070390A1 (ja) | 2016-10-12 | 2019-08-22 | 第一三共株式会社 | 抗robo4抗体と他剤を含む組成物 |
MX2019004371A (es) | 2016-10-13 | 2019-11-18 | Massachusetts Inst Technology | Anticuerpos que se unen a la proteina de envoltura del virus zika y usos de los mismos. |
IT201600111877A1 (it) | 2016-11-07 | 2018-05-07 | Biouniversa Srl | Anti-BAG3 antibodies in combination with inhibitors of immune check-point for therapeutic use |
UA126388C2 (uk) | 2016-11-18 | 2022-09-28 | Астеллас Фарма Інк. | Fab-фрагмент антитіла до muc1 людини |
BR112019011794A2 (pt) | 2016-12-12 | 2019-10-29 | Daiichi Sankyo Co Ltd | composição farmacêutica, e, método terapêutico. |
BR112019011988A2 (pt) | 2016-12-13 | 2019-11-05 | Astellas Pharma Inc | anticorpo anti-cd73 humana |
AU2017378451A1 (en) | 2016-12-15 | 2019-07-04 | The National Institute for Biotechnology in the Negev Ltd. | Anti-PCNA monoclonal antibodies and use thereof |
US11618785B2 (en) | 2016-12-22 | 2023-04-04 | Daiichi Sankyo Company, Limited | Anti-CD3 antibody and molecules comprising the antibody |
US20180179490A1 (en) | 2016-12-27 | 2018-06-28 | Miltenyi Biotec Gmbh | CELL COMPOSITION DEPLETED FROM TCRab and CD45RA POSITIVE CELLS |
WO2018129284A1 (en) | 2017-01-05 | 2018-07-12 | The Johns Hopkins University | Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (psma) |
CA3050668C (en) | 2017-01-17 | 2023-08-15 | Daiichi Sankyo Company, Limited | Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate |
WO2018140510A1 (en) | 2017-01-25 | 2018-08-02 | Biogen Ma Inc. | Compositions and methods for treatment of stroke and other cns disorders |
WO2018147245A1 (ja) | 2017-02-07 | 2018-08-16 | 第一三共株式会社 | 抗gprc5d抗体及び該抗体を含む分子 |
EP3363459A1 (en) | 2017-02-17 | 2018-08-22 | Alexander Klimka | Polypeptide epitopes of s. aureus and respective monoclonal antibodies for the treatment of infections and immune-diagnosis |
CN111148760A (zh) | 2017-02-27 | 2020-05-12 | 卡拉斯医疗有限公司 | 抗体构建体和治疗癌症的方法 |
CN110475569B (zh) | 2017-02-28 | 2023-11-21 | 第一三共株式会社 | Egfr-tki耐受性的非小细胞肺癌的治疗剂以及抗her3抗体-药物偶联物的应用 |
CN110753702B (zh) | 2017-03-15 | 2022-09-20 | 清华大学 | 抗trkb抗体 |
JOP20180021A1 (ar) | 2017-03-16 | 2019-01-30 | Janssen Biotech Inc | الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها |
WO2018167283A1 (en) | 2017-03-17 | 2018-09-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling |
US11879014B2 (en) | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
SG11201908996YA (en) | 2017-03-30 | 2019-10-30 | Ecs Progastrin Sa | Compositions and methods for detecting lung cancer |
TWI782000B (zh) | 2017-03-30 | 2022-11-01 | 日商第一三共股份有限公司 | 抗gpr20抗體、其製造方法及其應用 |
KR102351556B1 (ko) | 2017-03-30 | 2022-01-14 | 프로가스트린 에 캔서스 에스.에이 알.엘. | 프로가스트린 결합 분자를 사용하는 전립선암의 검출 및 치료를 위한 조성물 및 방법 |
US10722589B2 (en) | 2017-04-03 | 2020-07-28 | Covagen Ag | FGFR3 binding molecules |
WO2018185516A1 (en) | 2017-04-05 | 2018-10-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy |
EP3610264A1 (en) | 2017-04-13 | 2020-02-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma |
WO2018189403A1 (en) | 2017-04-14 | 2018-10-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cancer |
US20190016810A1 (en) | 2017-05-11 | 2019-01-17 | Cytodyn Inc. | Methods for treating or preventing graft-versus-host disease involving the administration of anti-ccr5 receptor agents |
TWI794230B (zh) | 2017-05-15 | 2023-03-01 | 日商第一三共股份有限公司 | 抗cdh6抗體及抗cdh6抗體-藥物結合物、以及其製造方法 |
JP7235733B2 (ja) | 2017-06-05 | 2023-03-08 | ヤンセン バイオテツク,インコーポレーテツド | Pd-1に特異的に結合する抗体、及び使用方法 |
WO2018226685A2 (en) | 2017-06-06 | 2018-12-13 | Dana-Farber Cancer Institute, Inc. | Methods for sensitizing cancer cells to t cell-mediated killing by modulating molecular pathways |
WO2019005503A1 (en) | 2017-06-29 | 2019-01-03 | Rutgers, The State University Of New Jersey | COMPOSITIONS AND METHODS TARGETING G12 SIGNALING FOR BRONCHODILATORY THERAPY |
WO2019004487A1 (ja) | 2017-06-30 | 2019-01-03 | 国立大学法人北海道大学 | 成長障害を生じない小児骨粗鬆症治療薬 |
TWI795415B (zh) | 2017-07-07 | 2023-03-11 | 日商安斯泰來製藥股份有限公司 | 新穎的抗人類CEACAM5抗體Fab片段 |
WO2019018744A1 (en) | 2017-07-21 | 2019-01-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | IMMUNOGENIC COMPOSITIONS OF NEISSERIA MENINGITIDIS |
SG11202000759XA (en) | 2017-07-27 | 2020-02-27 | Daiichi Sankyo Co Ltd | Anti-cd147 antibody |
US20210024623A1 (en) | 2017-07-28 | 2021-01-28 | Intrepida Bio, Inc. | Anti-bag3 antibodies as therapeutic reagent in cardiovascular disease |
JP6889328B2 (ja) | 2017-07-31 | 2021-06-18 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 三次元構造に基づくヒト化方法 |
EP3444272A1 (en) | 2017-08-17 | 2019-02-20 | International-Drug-Development-Biotech | Treatment of ck8 positive cancers in relation with k-ras gene status |
KR20200044044A (ko) | 2017-08-23 | 2020-04-28 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트의 제제 및 그 동결 건조 방법 |
KR20200039783A (ko) | 2017-08-23 | 2020-04-16 | 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 | Cxcr5에 결합하는 키메라 항원 수용체 및 car-t 세포 |
CN117865839A (zh) | 2017-08-31 | 2024-04-12 | 第一三共株式会社 | 制备抗体-药物缀合物的新方法 |
WO2019044947A1 (ja) | 2017-08-31 | 2019-03-07 | 第一三共株式会社 | 抗体-薬物コンジュゲートの改良製造方法 |
US10610585B2 (en) | 2017-09-26 | 2020-04-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating and preventing HIV |
IL301638B1 (en) | 2017-09-29 | 2024-05-01 | Daiichi Sankyo Co Ltd | Conjugation of an antibody with a pyrrolobenzodiazepine derivative |
WO2019069561A1 (ja) | 2017-10-03 | 2019-04-11 | 公益財団法人東京都医学総合研究所 | インフルエンザに対する医薬 |
CN111447952A (zh) | 2017-10-05 | 2020-07-24 | 第一三共株式会社 | 用于细胞毒性t细胞耗竭的组合物 |
KR101966362B1 (ko) | 2017-10-20 | 2019-04-05 | 주식회사 녹십자 | 항-msln 항체 및 이를 포함하는 암 치료용 약학적 조성물 |
WO2019094595A2 (en) | 2017-11-09 | 2019-05-16 | Pinteon Therapeutics Inc. | Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies |
JP7359449B2 (ja) | 2017-11-30 | 2023-10-11 | センチュリオン バイオファーマ コーポレイション | オーリスタチンe誘導体のアルブミン結合プロドラッグ |
JP7442821B2 (ja) | 2017-11-30 | 2024-03-05 | センチュリオン バイオファーマ コーポレイション | メイタンシノイド系薬物送達システム |
WO2019106126A1 (en) | 2017-12-01 | 2019-06-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Mdm2 modulators for the diagnosis and treatment of liposarcoma |
WO2019110662A1 (en) | 2017-12-05 | 2019-06-13 | Progastrine Et Cancers S.À R.L. | Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer |
WO2019121872A1 (en) | 2017-12-20 | 2019-06-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of liver cancer |
US20190225689A1 (en) | 2018-01-22 | 2019-07-25 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-pd-1 antibodies |
WO2019145537A1 (en) | 2018-01-26 | 2019-08-01 | Ecs-Progastrin Sa | Combination of progastrin detection with other cancer biomarkers in cancer diagnosis |
US11834487B2 (en) | 2018-02-12 | 2023-12-05 | Hadasit Medical Research Services & Development Ltd. | Modulation of SLAMF6 splice variants for cancer therapy |
WO2019158512A1 (en) | 2018-02-13 | 2019-08-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the prognosis and the treatment of glioblastoma |
JP7474709B2 (ja) | 2018-02-27 | 2024-04-25 | インサイト・コーポレイション | A2a/a2b阻害剤としてのイミダゾピリミジン及びトリアゾロピリミジン |
TW202000699A (zh) | 2018-02-27 | 2020-01-01 | 瑞士商Ecs前胃泌激素公司 | 將前胃泌激素作為生物標記用於免疫療法的技術 |
TW202000232A (zh) | 2018-03-05 | 2020-01-01 | 學校法人埼玉醫科大學 | 用以治療或預防異位性骨化之醫藥組成物 |
EP3775206A1 (en) | 2018-03-28 | 2021-02-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating cancer |
EP3775908A1 (en) | 2018-04-13 | 2021-02-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting outcome and treatment of patients suffering from prostate cancer or breast cancer |
EP3781590A1 (en) | 2018-04-20 | 2021-02-24 | Medizinische Hochschule Hannover | Chimeric antigen receptor and car-t cells that bind a herpes virus antigen |
WO2019207066A1 (en) | 2018-04-26 | 2019-10-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for the treatment of sjögren's syndrome |
WO2019211370A1 (en) | 2018-05-03 | 2019-11-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating cancer |
WO2019211369A1 (en) | 2018-05-03 | 2019-11-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating cancer |
CN112088167A (zh) | 2018-05-09 | 2020-12-15 | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 特异性针对人类连接蛋白4的抗体 |
AU2019268022A1 (en) | 2018-05-11 | 2020-11-26 | Astellas Pharma Inc. | Nucleic acid for treating mite allergy |
US20210163549A1 (en) | 2018-05-11 | 2021-06-03 | Astellas Pharma Inc. | Nucleic acid for treating crustacean allergy |
US20210340276A1 (en) | 2018-05-17 | 2021-11-04 | Astellas Pharma Inc. | Complex having anti-human muc1 antibody fab fragment, peptide linker and/or ligand |
CA3100731A1 (en) | 2018-05-18 | 2019-11-21 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
CN112513085B (zh) | 2018-05-24 | 2024-06-18 | 詹森生物科技公司 | Psma结合剂及其用途 |
EA202092849A1 (ru) | 2018-05-24 | 2021-03-16 | Янссен Байотек, Инк. | Моноспецифические и мультиспецифические антитела к tmeff2 и их применение |
JP7530299B2 (ja) | 2018-05-24 | 2024-08-07 | ヤンセン バイオテツク,インコーポレーテツド | 抗cd3抗体及びその使用 |
SG11202011243XA (en) | 2018-05-28 | 2020-12-30 | Daiichi Sankyo Co Ltd | Treatment of her2-mutated cancer by administering anti-her2 antibody-drug conjugate |
TW202015726A (zh) | 2018-05-30 | 2020-05-01 | 瑞士商諾華公司 | Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法 |
CA3099900A1 (en) | 2018-05-31 | 2019-12-05 | Daiichi Sankyo Company, Limited | Anti-human tlr7 antibody |
CU20200089A7 (es) | 2018-06-01 | 2021-07-02 | Novartis Ag | Moléculas de unión contra bcma |
EP3800999A4 (en) | 2018-06-04 | 2022-06-01 | Biogen MA Inc. | ANTI-VLA-4 ANTIBODIES WITH REDUCED EFFECTOR FUNCTION |
WO2019234099A1 (en) | 2018-06-06 | 2019-12-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing, predicting the outcome and treating a patient suffering from heart failure with preserved ejection fraction |
WO2019234221A1 (en) | 2018-06-08 | 2019-12-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia |
EP3810651A1 (en) | 2018-06-20 | 2021-04-28 | Incyte Corporation | Anti-pd-1 antibodies and uses thereof |
TW202016144A (zh) | 2018-06-21 | 2020-05-01 | 日商第一三共股份有限公司 | 包括cd3抗原結合片段之組成物及其用途 |
WO2020006408A1 (en) | 2018-06-29 | 2020-01-02 | Incyte Corporation | Formulations of an axl/mer inhibitor |
WO2020007898A1 (en) | 2018-07-04 | 2020-01-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating brain injury or neurodegenerative disease |
CN113166153A (zh) | 2018-07-05 | 2021-07-23 | 因赛特公司 | 作为a2a/a2b抑制剂的稠合吡嗪衍生物 |
CA3107417C (en) | 2018-07-25 | 2023-10-17 | Daiichi Sankyo Company, Limited | Effective method for manufacturing antibody-drug conjugate |
CN112512584A (zh) | 2018-07-27 | 2021-03-16 | 国立大学法人大阪大学 | 用于抑制衰老、预防、改善或治疗衰老相关疾病或症状、或者延长寿命的组合物 |
AU2019311596A1 (en) | 2018-07-27 | 2021-01-28 | Daiichi Sankyo Company, Limited | Protein recognizing drug moiety of antibody-drug conjugate |
BR112021001509A2 (pt) | 2018-07-31 | 2021-04-27 | Daiichi Sankyo Company, Limited | agente terapêutico para um tumor de cérebro metastásico |
US20210290775A1 (en) | 2018-08-06 | 2021-09-23 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and tubulin inhibitor |
US20220008549A1 (en) | 2018-09-06 | 2022-01-13 | Daiichi Sankyo Company, Limited | Novel cyclic dinucleotide derivative and antibody-drug conjugate thereof |
EP3854418A4 (en) | 2018-09-20 | 2022-07-27 | Daiichi Sankyo Company, Limited | TREATMENT OF HER3 MUTANT CANCER BY ADMINISTRATION OF AN ANTI-HER3 ANTIBODY-DRUG CONJUGATE |
WO2020059847A1 (ja) | 2018-09-21 | 2020-03-26 | 国立大学法人 東京医科歯科大学 | ヒトhmgb1に特異的に結合するヒトモノクローナル抗体、及びそれを含有するアルツハイマー病を治療又は予防するための医薬組成物 |
AU2019350536A1 (en) | 2018-09-27 | 2021-05-06 | Pierre Fabre Medicament | Sulfomaleimide-based linkers and corresponding conjugates |
CA3114179A1 (en) | 2018-09-28 | 2020-04-02 | Pierre Fabre Medicament | New immunocytokines for the treatment of cancer |
CN112839683B (zh) | 2018-10-10 | 2023-11-14 | 安斯泰来制药株式会社 | 含有标记部-抗人抗体Fab片段复合物的药物组合物 |
UY38407A (es) | 2018-10-15 | 2020-05-29 | Novartis Ag | Anticuerpos estabilizadores de trem2 |
JP2022505113A (ja) | 2018-10-18 | 2022-01-14 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 固形腫瘍の処置のためのβig-h3アンタゴニストと免疫チェックポイント阻害剤との組み合わせ |
BR112021008424A2 (pt) | 2018-10-31 | 2021-09-28 | Astellas Pharma Inc. | Anticorpo anti-fn14 humano |
EP3880706A1 (en) | 2018-11-12 | 2021-09-22 | MediaPharma S.r.l. | Bispecific antibodies directed against human 90k and either endosialin or her3 |
TW202031298A (zh) | 2018-11-14 | 2020-09-01 | 日商第一三共股份有限公司 | 抗cdh6抗體-吡咯并苯二氮呯衍生物結合物 |
TW202034959A (zh) | 2018-12-11 | 2020-10-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物與parp抑制劑之組合 |
JP2022515188A (ja) | 2018-12-21 | 2022-02-17 | エイム・イムノテック・インコーポレイテッド | がん治療のための組成物および方法 |
BR112021011894A2 (pt) | 2018-12-21 | 2021-09-08 | Daiichi Sankyo Company, Limited | Composição farmacêutica |
WO2020145227A1 (ja) | 2019-01-07 | 2020-07-16 | アステラス製薬株式会社 | 配位子、スペーサー、ペプチドリンカーおよび生物分子からなる複合体 |
MX2021008392A (es) | 2019-01-10 | 2021-10-26 | Janssen Biotech Inc | Neoantígenos prostaticos y sus usos. |
AU2020207664A1 (en) | 2019-01-13 | 2021-07-22 | University Of Rijeka Faculty Of Medicine | Antibodies specific to human Nectin-2 |
CA3125697A1 (en) | 2019-01-29 | 2020-08-06 | Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) | Treating the causative agent in adhesiogenesis |
TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
EP3924386A4 (en) | 2019-02-13 | 2023-01-04 | The Brigham & Women's Hospital, Inc. | ANTI-PERIPHERAL LYMPH NODE RESPONSIBLE ANTIBODIES AND USES THEREOF |
WO2020178193A1 (en) | 2019-03-01 | 2020-09-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method of treatment of sarcoidosis |
WO2020193441A1 (en) | 2019-03-22 | 2020-10-01 | Université de Paris | New inhibitors of lrrk2/pp1 interaction |
EP3949987A4 (en) | 2019-03-25 | 2023-02-22 | Daiichi Sankyo Company, Limited | ANTI-HER2 ANTIBODY PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE |
ES2967879T3 (es) | 2019-03-25 | 2024-05-06 | Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft | Mejora de la actividad de los linfocitos T citolíticos mediante la inhibición de EBAG9 |
US20220168440A1 (en) | 2019-03-25 | 2022-06-02 | Daiichi Sankyo Company, Limited | Antibody-pyrrolobenzodiazepine deprivative conjugate |
WO2020196712A1 (ja) | 2019-03-27 | 2020-10-01 | 第一三共株式会社 | 抗体-ピロロベンゾジアゼピン誘導体コンジュゲートとparp阻害剤の組み合わせ |
JPWO2020204033A1 (es) | 2019-04-01 | 2020-10-08 | ||
MX2021012003A (es) | 2019-04-02 | 2021-11-04 | Kenjockety Biotechnology Inc | Anticuerpos multiespecificos contra antigeno de cancer de la bomba de eflujo y composiciones, reactivos, kits y metodos relacionados con los mismos. |
EP3956022A1 (en) | 2019-04-19 | 2022-02-23 | Janssen Biotech, Inc. | Methods of treating prostate cancer with an anti- psma/cd3 antibody |
EP3962527A4 (en) | 2019-04-30 | 2023-11-01 | Senti Biosciences, Inc. | CHIMERIC RECEPTORS AND THEIR METHODS OF USE |
WO2020223121A1 (en) | 2019-04-30 | 2020-11-05 | Dana-Farber Cancer Institute, Inc. | Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents |
US20220259561A1 (en) | 2019-05-14 | 2022-08-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Regulatory t cells targeted by lymphotoxin alpha blocking agent and uses thereof |
SG11202112429PA (en) | 2019-05-29 | 2021-12-30 | Daiichi Sankyo Co Ltd | Dosage of an antibody-drug conjugate |
KR20220024729A (ko) | 2019-06-24 | 2022-03-03 | 노파르티스 아게 | B-세포 성숙 항원을 표적으로 하는 다중특이성 항체에 대한 투여 요법 및 병용 요법 |
US20210040210A1 (en) | 2019-07-26 | 2021-02-11 | Janssen Biotech, Inc. | Proteins Comprising Kallikrein Related Peptidase 2 Antigen Binding Domains And Their Uses |
EP4008350A4 (en) | 2019-07-26 | 2023-06-14 | Saitama Medical University | ANTIBODY RECOGNIZING THE EXTRACELLULAR REGION OF ALK2/ACVR1 |
WO2021019706A1 (ja) | 2019-07-31 | 2021-02-04 | 国立大学法人信州大学 | Car発現免疫細胞を含む細胞集団の製造方法 |
US20210030869A1 (en) | 2019-08-01 | 2021-02-04 | Incyte Corporation | Dosing regimen for an ido inhibitor |
MX2022001411A (es) | 2019-08-02 | 2022-03-25 | Cytodyn Inc | Metodos para tratar o prevenir canceres que implican la administracion de agentes receptores anti-ccr5. |
KR102433076B1 (ko) | 2019-08-12 | 2022-08-19 | 비온드 바이오로직스 엘티디 | Ilt2에 대한 항체 및 이의 용도 |
EP3792632A1 (en) | 2019-09-16 | 2021-03-17 | Vito NV | Immunotherapy markers |
TW202124446A (zh) | 2019-09-18 | 2021-07-01 | 瑞士商諾華公司 | 與entpd2抗體之組合療法 |
CN114502590A (zh) | 2019-09-18 | 2022-05-13 | 诺华股份有限公司 | Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法 |
EP4034151A1 (en) | 2019-09-27 | 2022-08-03 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Use of müllerian inhibiting substance inhibitors for treating cancer |
US11760801B2 (en) | 2019-09-27 | 2023-09-19 | Janssen Biotech, Inc. | Anti-CEACAM antibodies and uses thereof |
US20240190961A1 (en) | 2019-10-25 | 2024-06-13 | Daiichi Sankyo Company, Limited | Combination of anti-garp antibody and immunomodulator |
KR20220113386A (ko) | 2019-11-15 | 2022-08-12 | 플라이언트 테라퓨틱스, 인크. | 인테그린의 활성화를 위한 조성물 및 방법 |
PE20221182A1 (es) | 2019-11-18 | 2022-08-05 | Janssen Biotech Inc | Vacunas basadas en calr y jak2 mutantes y sus usos |
CA3159975A1 (en) * | 2019-12-10 | 2021-06-17 | CCOA Therapeutics Inc. | Humanized anti-glycoprotein ib alpha (gpibalpha) antibodies |
CA3164996A1 (en) | 2019-12-20 | 2021-06-14 | Novarock Biotherapeutics, Ltd. | Anti-interleukin-23 p19 antibodies and methods of use thereof |
WO2021138512A1 (en) | 2020-01-03 | 2021-07-08 | Incyte Corporation | Combination therapy comprising a2a/a2b and pd-1/pd-l1 inhibitors |
WO2021140173A1 (en) | 2020-01-10 | 2021-07-15 | Biouniversa S.R.L. | Methods and uses for treating fibrotic solid tumors with bags inhibitors |
WO2021156329A1 (en) | 2020-02-05 | 2021-08-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of treatment of cancer disease by targeting an epigenetic factor |
TW202140012A (zh) | 2020-02-12 | 2021-11-01 | 比利時商健生藥品公司 | 用於治療尿路上皮癌的fgfr酪胺酸激酶抑制劑和抗pd1藥劑 |
TW202144389A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在多發性骨髓瘤中表現之新抗原及其用途 |
TW202144388A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在卵巢癌中表現之新抗原及其用途 |
US20230085883A1 (en) | 2020-03-03 | 2023-03-23 | Active Biotech Ab | Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy |
AU2021230385A1 (en) | 2020-03-06 | 2022-09-22 | Incyte Corporation | Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors |
WO2021177438A1 (ja) | 2020-03-06 | 2021-09-10 | 第一三共株式会社 | 新規環状ジヌクレオチド誘導体を含む抗体薬物コンジュゲート |
KR20220167276A (ko) | 2020-03-10 | 2022-12-20 | 매사추세츠 인스티튜트 오브 테크놀로지 | NPM1c-양성 암의 면역치료를 위한 조성물 및 방법 |
EP4233893A3 (en) | 2020-03-13 | 2023-09-27 | Janssen Biotech, Inc. | Materials and methods for binding siglec-3/cd33 |
US11045546B1 (en) | 2020-03-30 | 2021-06-29 | Cytodyn Inc. | Methods of treating coronavirus infection |
EP4130036A4 (en) | 2020-03-30 | 2024-05-15 | National Cancer Center | ANTIBODY-DRUG CONJUGATE |
EP3889183A1 (en) | 2020-04-01 | 2021-10-06 | Pierre Fabre Medicament | A protein complex comprising an immunocytokine |
WO2021205438A1 (en) | 2020-04-06 | 2021-10-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Antibodies to nkp46 and constructs thereof for treatment of cancers and infections |
TW202144429A (zh) | 2020-05-14 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗cd25抗體、其抗原結合片段及其醫藥用途 |
JP2023526529A (ja) | 2020-05-19 | 2023-06-21 | アンスティテュ・クリー | サイトカイン放出症候群の診断及び処置の方法 |
AU2021281828A1 (en) | 2020-05-27 | 2023-02-02 | Arialys Therapeutics, Inc. | Anti-human NR1 antibody derivative |
MX2022014938A (es) | 2020-05-27 | 2023-03-06 | Janssen Biotech Inc | Proteínas que comprenden dominios de unión al antígeno de cd3 y usos de éstas. |
US20230192902A1 (en) | 2020-06-04 | 2023-06-22 | Kenjockety Biotechnology, Inc. | Abcg2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto |
WO2021260582A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and aurora b inhibitor |
EP4171651A1 (en) | 2020-06-24 | 2023-05-03 | AstraZeneca UK Limited | Combination of antibody-drug conjugate and atm inhibitor |
WO2021260583A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and dna-pk inhibitor |
JP2023542065A (ja) | 2020-06-24 | 2023-10-05 | アストラゼネカ ユーケー リミテッド | 抗体-薬物複合物及びcdk9阻害剤の組み合わせ |
KR20230043109A (ko) | 2020-06-24 | 2023-03-30 | 아스트라제네카 유케이 리미티드 | 항체-약물 접합체 및 atr 억제제의 조합 |
WO2021260139A1 (en) | 2020-06-25 | 2021-12-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of treatment and diagnostic of pathological conditions associated with intense stress |
AU2021307257A1 (en) | 2020-07-17 | 2023-03-09 | Daiichi Sankyo Company, Limited | Method for producing antibody-drug conjugate |
JPWO2022019259A1 (es) | 2020-07-20 | 2022-01-27 | ||
CN116209681A (zh) | 2020-07-29 | 2023-06-02 | 詹森生物科技公司 | 包含hla-g抗原结合结构域的蛋白质及其用途 |
RU2764216C1 (ru) * | 2020-08-10 | 2022-01-14 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Чувашский государственный университет имени И.Н. Ульянова" | Способ лечения гломерулонефритов с нефротическим синдромом рецидивирующего течения |
CN116096756A (zh) | 2020-08-12 | 2023-05-09 | 比昂生物制剂公司 | 针对ilt2的抗体及其用途 |
WO2022043312A1 (en) | 2020-08-24 | 2022-03-03 | Charité - Universitätsmedizin Berlin | Chimeric antigen receptor (car)-expressing cells recognizing cea |
JP2023540022A (ja) | 2020-08-24 | 2023-09-21 | シャリテ-ウニベルジテーツメディツィン ベルリン | チェックポイント阻害分子及び免疫刺激性サイトカインをコードするキメラ抗原受容体構築物、並びにCD44v6を認識するCAR発現細胞 |
WO2022051591A2 (en) | 2020-09-04 | 2022-03-10 | Novarock Biotherapeutics, Ltd. | Nectin-4 antibodies and uses thereof |
EP4210722A1 (en) | 2020-09-07 | 2023-07-19 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods of treatment of inflammatory bowel diseases |
JP2023545359A (ja) | 2020-09-12 | 2023-10-30 | アストラゼネカ・ユーケイ・リミテッド | 抗her2抗体-薬物複合体治療のためのスコアリング方法 |
WO2022075482A1 (ja) | 2020-10-05 | 2022-04-14 | 株式会社カイオム・バイオサイエンス | がん治療用医薬 |
TW202222350A (zh) | 2020-10-09 | 2022-06-16 | 英商阿斯特捷利康英國股份有限公司 | 抗體-藥物結合物及parp1選擇性抑制劑之組合 |
UY39467A (es) | 2020-10-13 | 2022-04-29 | Janssen Biotech Inc | Inmunidad mediada por células t de bioingeniería, materiales y otros métodos para modular el grupo de diferenciación iv y / o viii |
EP4232064A1 (en) | 2020-10-21 | 2023-08-30 | Institut National de la Santé et de la Recherche Médicale (INSERM) | C-terminal sparc fragments for treating cancer |
TW202233672A (zh) | 2020-10-22 | 2022-09-01 | 美商健生生物科技公司 | 包括類δ配體3(DLL3)抗原結合區之蛋白質及其用途 |
WO2022097090A1 (en) | 2020-11-05 | 2022-05-12 | Novartis Ag | Dosing regimen for combination therapies with multispecific antibodies targeting b-cell maturation antigen and gamma secretase inhibitors |
WO2022096633A1 (en) | 2020-11-06 | 2022-05-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosis and treating polycystic ovary syndrome (pcos) |
EP4245321A1 (en) | 2020-11-11 | 2023-09-20 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate with anti-sirpalpha antibody |
US20230398230A1 (en) | 2020-11-12 | 2023-12-14 | Daiichi Sankyo Company, Limited | Treatment of mesothelioma by administration of anti-b7-h3 antibody-drug conjugate |
JP7078237B1 (ja) | 2020-11-16 | 2022-05-31 | アステラス製薬株式会社 | 抗tspan8-抗cd3二重特異性抗体及び抗tspan8抗体 |
EP4251282A1 (en) | 2020-11-27 | 2023-10-04 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for diagnosis and monitoring of toxic epidermal necrolysis |
CA3203587A1 (en) | 2020-11-30 | 2022-06-02 | Incyte Corporation | Combination therapy with an anti-cd19 antibody and parsaclisib |
WO2022115120A1 (en) | 2020-11-30 | 2022-06-02 | Incyte Corporation | Combination therapy with an anti-cd19 antibody and parsaclisib |
JPWO2022124247A1 (es) | 2020-12-09 | 2022-06-16 | ||
MX2023007850A (es) | 2020-12-29 | 2023-09-11 | Incyte Corp | Terapia combinada que comprende inhibidores de adora2a/adora2b (a2a/a2b), inhibidores de muerte programada/ligando 1 de muerte programada (pd-1/pd-l1) y anticuerpos de cumulo de diferenciacion 73 (anti-cd73). |
WO2022153212A1 (en) | 2021-01-13 | 2022-07-21 | Axon Neuroscience Se | Antibodies neutralizing sars-cov-2 |
WO2022153194A1 (en) | 2021-01-13 | 2022-07-21 | Memorial Sloan Kettering Cancer Center | Antibody-pyrrolobenzodiazepine derivative conjugate |
US20240115721A1 (en) | 2021-01-13 | 2024-04-11 | Memorial Sloan Kettering Cancer Center | Anti-dll3 antibody-drug conjugate |
EP4284838A2 (en) | 2021-01-28 | 2023-12-06 | Janssen Biotech, Inc. | Psma binding proteins and uses thereof |
US20240141060A1 (en) | 2021-01-29 | 2024-05-02 | Novartis Ag | Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof |
TW202241454A (zh) | 2021-02-01 | 2022-11-01 | 日商第一三共股份有限公司 | 抗體-免疫賦活化劑共軛物之新穎製造方法 |
WO2022172267A1 (en) | 2021-02-11 | 2022-08-18 | Nectin Therapeutics Ltd. | Antibodies against cd112r and uses thereof |
CA3208905A1 (en) | 2021-02-12 | 2022-08-18 | Boehringer Ingelheim International Gmbh | Complement c3 antigen binding proteins |
US20220378929A1 (en) | 2021-02-25 | 2022-12-01 | MediBoston Limted | Anti-her2 antibody-drug conjugates and uses thereof |
CN117425674A (zh) | 2021-03-02 | 2024-01-19 | 丹娜法伯癌症研究院 | 治疗红细胞疾患的方法 |
EP4305064A1 (en) | 2021-03-12 | 2024-01-17 | Fibrosys S.r.l. | Monoclonal antibodies for the treatment of viral infections |
KR20230157983A (ko) | 2021-03-12 | 2023-11-17 | 다이이찌 산쿄 가부시키가이샤 | 당사슬 및 당사슬을 포함하는 의약품의 제조 방법 |
KR20230160314A (ko) | 2021-03-24 | 2023-11-23 | 얀센 바이오테크 인코포레이티드 | Cd22 및 cd79b를 표적화하는 항체 |
JP2024513172A (ja) | 2021-03-26 | 2024-03-22 | ヤンセン バイオテツク,インコーポレーテツド | 対らせん状細線維タウに対するヒト化抗体及びその使用 |
WO2022218998A1 (en) | 2021-04-13 | 2022-10-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for treating hepatitis b and d virus infection |
JP2024513921A (ja) | 2021-04-14 | 2024-03-27 | ヴィラリス・セラピューティクス・インコーポレイテッド | 抗cd122抗体及びその使用 |
CN117222672A (zh) | 2021-04-22 | 2023-12-12 | 安斯泰来制药株式会社 | 抗cldn4-抗cd137双特异性抗体 |
US20240280561A1 (en) | 2021-06-08 | 2024-08-22 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating and/or identifying an agent for treating intestinal cancers |
CN113361141B (zh) * | 2021-07-11 | 2022-02-18 | 西南石油大学 | 一种dna图谱算法的改进试验方法 |
PE20240727A1 (es) | 2021-08-27 | 2024-04-15 | Janssen Biotech Inc | Anticuerpos anti-psma y usos de estos |
MX2024003277A (es) | 2021-09-15 | 2024-04-04 | Daiichi Sankyo Company Ltd | Conjugado de anticuerpo-farmaco para usarse en metodos de tratamiento del cancer resistente a la quimioterapia. |
WO2023041744A1 (en) | 2021-09-17 | 2023-03-23 | Institut Curie | Bet inhibitors for treating pab1 deficient cancer |
EP4405392A1 (en) | 2021-09-24 | 2024-07-31 | Janssen Biotech, Inc. | Proteins comprising cd20 binding domains, and uses thereof |
WO2023052541A1 (en) | 2021-09-30 | 2023-04-06 | Imcheck Therapeutics | Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy |
WO2023068226A1 (ja) | 2021-10-18 | 2023-04-27 | 第一三共株式会社 | 抗cd37抗体-薬物コンジュゲート |
WO2023073084A1 (en) | 2021-10-27 | 2023-05-04 | Imcheck Therapeutics | Butyrophilin (btn) 3a activating antibodies for use in methods for treating infectious disorders |
EP4177266A1 (en) | 2021-11-05 | 2023-05-10 | Katholieke Universiteit Leuven | Neutralizing anti-sars-cov-2 human antibodies |
IL312875A (en) | 2021-11-18 | 2024-07-01 | Astrazeneca Uk Ltd | A combination of an antibody-drug conjugate and a selective PARP1 inhibitor |
WO2023089032A1 (en) | 2021-11-19 | 2023-05-25 | Institut Curie | Methods for the treatment of hrd cancer and brca-associated cancer |
WO2023097119A2 (en) | 2021-11-29 | 2023-06-01 | Dana-Farber Cancer Institute, Inc. | Methods and compositions to modulate riok2 |
WO2023099763A1 (en) | 2021-12-03 | 2023-06-08 | Institut Curie | Sirt6 inhibitors for use in treating resistant hrd cancer |
JP7235262B1 (ja) | 2021-12-07 | 2023-03-08 | 国立大学法人大阪大学 | 抗体又はその抗原結合性断片 |
WO2023105528A1 (en) | 2021-12-12 | 2023-06-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Antibodies specific to ceacam1 |
TW202334231A (zh) | 2021-12-22 | 2023-09-01 | 德商莫菲西斯公司 | 抗cd19抗體療法的治療範例 |
CA3240724A1 (en) | 2021-12-28 | 2023-07-06 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and atr inhibitor |
WO2023126822A1 (en) | 2021-12-28 | 2023-07-06 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and rasg12c inhibitor |
WO2023152581A1 (en) | 2022-02-09 | 2023-08-17 | Janssen Biotech, Inc. | Method of treating cancer with psmaxcd3 antibody |
WO2023166081A1 (en) | 2022-03-02 | 2023-09-07 | Heidelberg Immunotherapeutics Gmbh | Vaccine comprising an antibody or an fc-containing fusion protein comprising an fc part of an antibody |
WO2023175614A1 (en) | 2022-03-15 | 2023-09-21 | Yeda Research And Development Co. Ltd. | Anti glucocorticoid-induced tnfr-related (gitr) protein antibodies and uses thereof |
WO2023175483A1 (en) | 2022-03-16 | 2023-09-21 | Astrazeneca Uk Limited | A scoring method for an anti-trop2 antibody‑drug conjugate therapy |
WO2023209591A1 (en) | 2022-04-27 | 2023-11-02 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor |
TW202400650A (zh) | 2022-05-11 | 2024-01-01 | 日商第一三共股份有限公司 | 抗體與cd47抑制劑之組合 |
WO2023228095A1 (en) | 2022-05-24 | 2023-11-30 | Daiichi Sankyo Company, Limited | Dosage regimen of an anti-cdh6 antibody-drug conjugate |
WO2024013723A1 (en) | 2022-07-15 | 2024-01-18 | Pheon Therapeutics Ltd | Antibody drug conjugates that bind cdcp1 and uses thereof |
TW202412859A (zh) | 2022-07-28 | 2024-04-01 | 英商阿斯特捷利康英國股份有限公司 | 抗體-藥物結合物及雙特異性檢查點抑制劑之組合 |
US20240101718A1 (en) | 2022-09-28 | 2024-03-28 | Incyte Corporation | Anti-pd-1/lag-3 bispecific antibodies and uses thereof |
WO2024074498A1 (en) | 2022-10-04 | 2024-04-11 | Imcheck Therapeutics | Combination of a btn3a activating antibody, a bcl2 inhibitor and hypomethylating agent for use in treating cancer |
WO2024116094A1 (en) | 2022-11-30 | 2024-06-06 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugates and dnmt inhibitors |
WO2024121380A1 (en) | 2022-12-08 | 2024-06-13 | Pierre Fabre Medicament | Vaccinal composition and adjuvant |
WO2024127366A1 (en) | 2022-12-16 | 2024-06-20 | Pheon Therapeutics Ltd | Antibodies to cub domain-containing protein 1 (cdcp1) and uses thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
JPS6033453B2 (ja) * | 1978-08-17 | 1985-08-02 | 富士電機株式会社 | 魚切断加工自動化装置 |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS6014678A (ja) * | 1983-07-04 | 1985-01-25 | Taiheiyo Kogyo Kk | 電磁弁 |
GB8607679D0 (en) * | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
GB2188941B (en) * | 1986-04-14 | 1990-06-06 | Bayer Ag | Monoclonal antibodies recognizing human interleukin-2-receptor |
DK554986A (da) * | 1986-11-19 | 1988-07-18 | Novo Industri As | Human-human hybride cellelinier samt dermed producerede monoklonale cancerantistoffer |
GB8720833D0 (en) * | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
AU618989B2 (en) * | 1988-02-12 | 1992-01-16 | British Technology Group Limited | Improvements in or relating to antibodies |
JPH02503867A (ja) * | 1988-04-15 | 1990-11-15 | プロテイン デザイン ラブズ インコーポレーテッド | Il‐2レセプター特異的キメラ抗体 |
JP5598363B2 (ja) | 2011-02-15 | 2014-10-01 | ソニー株式会社 | 記憶装置およびその動作方法 |
-
1989
- 1989-11-27 IL IL162181A patent/IL162181A/en not_active IP Right Cessation
- 1989-12-27 IL IL92904A patent/IL92904A0/xx not_active IP Right Cessation
- 1989-12-28 CA CA002328851A patent/CA2328851C/en not_active Expired - Lifetime
- 1989-12-28 AT AT95105609T patent/ATE183753T1/de not_active IP Right Cessation
- 1989-12-28 DE DE98204240.0T patent/DE98204240T1/de active Pending
- 1989-12-28 IE IE20000331A patent/IE20000331A1/en unknown
- 1989-12-28 WO PCT/US1989/005857 patent/WO1990007861A1/en active IP Right Grant
- 1989-12-28 EP EP10185689A patent/EP2341080A1/en not_active Withdrawn
- 1989-12-28 CA CA002006865A patent/CA2006865C/en not_active Expired - Lifetime
- 1989-12-28 EP EP04076438.3A patent/EP1491556B1/en not_active Expired - Lifetime
- 1989-12-28 EP EP98204240.0A patent/EP0939127B1/en not_active Expired - Lifetime
- 1989-12-28 DE DE200712000037 patent/DE122007000037I1/de active Pending
- 1989-12-28 DE DE04076438.3T patent/DE04076438T1/de active Pending
- 1989-12-28 YU YU248989A patent/YU48700B/sh unknown
- 1989-12-28 KR KR1019900701939A patent/KR0178385B1/ko not_active IP Right Cessation
- 1989-12-28 ES ES90903576T patent/ES2081974T5/es not_active Expired - Lifetime
- 1989-12-28 SI SI8912489A patent/SI8912489B/sl unknown
- 1989-12-28 PT PT92758A patent/PT92758B/pt active IP Right Grant
- 1989-12-28 EP EP95105609A patent/EP0682040B1/en not_active Revoked
- 1989-12-28 ES ES98204240.0T patent/ES2492815T3/es not_active Expired - Lifetime
- 1989-12-28 DE DE68925536T patent/DE68925536T3/de not_active Expired - Lifetime
- 1989-12-28 EP EP04076439.1A patent/EP1477497B1/en not_active Expired - Lifetime
- 1989-12-28 DE DE1989625536 patent/DE122006000036I1/de active Pending
- 1989-12-28 DE DE122005000007C patent/DE122005000007I2/de active Active
- 1989-12-28 DE DE2000175005 patent/DE10075005I2/de active Active
- 1989-12-28 DE DE68929061T patent/DE68929061T2/de not_active Expired - Lifetime
- 1989-12-28 JP JP2503677A patent/JP2828340B2/ja not_active Ceased
- 1989-12-28 DE DE04076439.1T patent/DE04076439T1/de active Pending
- 1989-12-28 ES ES04076439.1T patent/ES2523810T3/es not_active Expired - Lifetime
- 1989-12-28 DE DE122005000057C patent/DE122005000057I2/de active Active
- 1989-12-28 DE DE19975047C patent/DE19975047I2/de active Active
- 1989-12-28 AU AU51532/90A patent/AU647383B2/en not_active Expired
- 1989-12-28 ES ES04076438.3T patent/ES2440825T3/es not_active Expired - Lifetime
- 1989-12-28 DE DE2000175038 patent/DE10075038I2/de active Active
- 1989-12-28 CN CN89109618A patent/CN1057013C/zh not_active Expired - Lifetime
- 1989-12-28 AT AT90903576T patent/ATE133452T1/de active
- 1989-12-28 ZA ZA899956A patent/ZA899956B/xx unknown
- 1989-12-28 RU SU4895847/13A patent/RU2126046C1/ru active
- 1989-12-28 ES ES95105609T patent/ES2136760T3/es not_active Expired - Lifetime
- 1989-12-28 DE DE68925536A patent/DE68925536D1/de not_active Expired - Lifetime
- 1989-12-28 DE DE122009000071C patent/DE122009000071I1/de active Pending
- 1989-12-28 EP EP90903576A patent/EP0451216B9/en not_active Expired - Lifetime
- 1989-12-28 MC MC@@@@D patent/MC2146A1/xx unknown
-
1990
- 1990-01-04 NZ NZ314793A patent/NZ314793A/xx unknown
- 1990-01-04 NZ NZ231984A patent/NZ231984A/en unknown
- 1990-01-17 DD DD90337159A patent/DD296964A5/de unknown
-
1991
- 1991-05-20 FI FI912436A patent/FI108797B/fi active Protection Beyond IP Right Term
- 1991-06-19 NO NO19912385A patent/NO310473B1/no not_active IP Right Cessation
- 1991-06-19 DK DK119191A patent/DK119191A/da not_active Application Discontinuation
- 1991-12-31 CZ CS914186A patent/CZ418691A3/cs unknown
-
1992
- 1992-01-20 BG BG095784A patent/BG61095B2/xx unknown
- 1992-09-26 HR HRP-2489/89A patent/HRP920500B1/xx not_active IP Right Cessation
-
1995
- 1995-06-16 HU HU95P/P00236P patent/HU211174A9/hu active Protection Beyond IP Right Term
-
1996
- 1996-04-13 SG SG1996007855A patent/SG78258A1/en unknown
-
1998
- 1998-01-12 JP JP00433498A patent/JP3604058B2/ja not_active Expired - Lifetime
- 1998-07-16 DK DK199800941A patent/DK174317B1/da not_active IP Right Cessation
- 1998-12-28 HK HK98115967A patent/HK1014718A1/xx not_active IP Right Cessation
-
1999
- 1999-07-02 LU LU90411C patent/LU90411I2/fr unknown
- 1999-07-14 NL NL990020C patent/NL990020I2/nl unknown
-
2000
- 2000-02-11 LU LU90528C patent/LU90528I2/fr unknown
- 2000-02-11 NL NL300005C patent/NL300005I2/nl unknown
- 2000-11-03 NL NL300023C patent/NL300023I2/nl unknown
- 2000-11-09 LU LU90676C patent/LU90676I2/fr unknown
-
2001
- 2001-12-17 NO NO2001024C patent/NO2001024I1/no unknown
- 2001-12-17 NO NO2001026C patent/NO2001026I2/no unknown
- 2001-12-17 NO NO2001025C patent/NO2001025I2/no unknown
-
2003
- 2003-01-20 JP JP2003011706A patent/JP2003245091A/ja not_active Withdrawn
- 2003-01-20 JP JP2003011705A patent/JP2003245090A/ja not_active Withdrawn
-
2005
- 2005-02-04 LU LU91139C patent/LU91139I2/fr unknown
- 2005-02-10 NL NL300173C patent/NL300173I2/nl unknown
- 2005-02-18 NO NO2005005C patent/NO2005005I2/no unknown
- 2005-12-02 LU LU91208C patent/LU91208I2/fr unknown
- 2005-12-07 NO NO2005026C patent/NO2005026I2/no unknown
- 2005-12-12 NL NL300213C patent/NL300213I2/nl unknown
-
2006
- 2006-08-07 NL NL300239C patent/NL300239I2/nl unknown
- 2006-08-07 NO NO2006009C patent/NO2006009I2/no unknown
- 2006-08-07 LU LU91272C patent/LU91272I2/fr unknown
-
2007
- 2007-03-02 JP JP2007053539A patent/JP2007145863A/ja not_active Withdrawn
- 2007-04-11 LU LU91333C patent/LU91333I2/fr unknown
- 2007-04-18 NL NL300279C patent/NL300279I2/nl unknown
- 2007-04-18 NO NO2007006C patent/NO2007006I2/no unknown
-
2009
- 2009-04-21 JP JP2009103471A patent/JP2009165488A/ja not_active Withdrawn
- 2009-11-12 NO NO2009026C patent/NO2009026I1/no unknown
- 2009-11-19 NL NL300426C patent/NL300426I1/nl unknown
- 2009-12-09 LU LU91627C patent/LU91627I2/fr unknown
-
2014
- 2014-09-17 FR FR14C0070C patent/FR14C0070I1/fr active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI108797B (fi) | Menetelmiä humanisoitujen immunoglobuliinien tuottamiseksi sekä menetelmissä käyttökelpoinen polynukleotidimolekyyli ja solulinja | |
AU631545B2 (en) | Il-2 receptor-specific chimeric antibodies | |
EP0781845B1 (en) | Anti-human milk fat globule humanised antibodies and processes for their production | |
EP0566647B1 (en) | Improved humanized immunoglobulins | |
EP0794966B1 (en) | Humanized antibodies to cd38 | |
WO1993001289A1 (en) | Humanized interleukin-2 receptors antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
SPCF | Supplementary protection certificate application filed |
Spc suppl protection certif: L20020014 |
|
SPCF | Supplementary protection certificate application filed |
Spc suppl protection certif: L20050004 |
|
SPCF | Supplementary protection certificate application filed |
Spc suppl protection certif: L20050028 |
|
SPCF | Supplementary protection certificate application filed |
Spc suppl protection certif: L20060010 |
|
PC | Transfer of assignment of patent |
Owner name: PDL BIOPHARMA, INC. Free format text: PDL BIOPHARMA, INC. |
|
SPCF | Supplementary protection certificate application filed |
Free format text: SPC L20070013 Spc suppl protection certif: L20070013 |
|
SPCG | Supplementary protection certificate granted |
Spc suppl protection certif: L205 Extension date: 20140728 |
|
SPCG | Supplementary protection certificate granted |
Spc suppl protection certif: L209 Extension date: 20130303 Spc suppl protection certif: L210 Extension date: 20140813 |
|
SPCG | Supplementary protection certificate granted |
Spc suppl protection certif: NUMBER:215 Spc suppl protection certif: NUMBER:216 |
|
SPCG | Supplementary protection certificate granted |
Spc suppl protection certif: NUMBER:228 Spc suppl protection certif: NUMBER:227 |
|
SPCF | Supplementary protection certificate application filed |
Free format text: SPC C20090039 Spc suppl protection certif: C20090039 |
|
SPCG | Supplementary protection certificate granted |
Spc suppl protection certif: 282 Extension date: 20141228 |
|
SPCG | Supplementary protection certificate granted |
Spc suppl protection certif: 282 Extension date: 20141228 |
|
SPCL | Withdrawal, rejection or dismissal of a supplementary protection certificate |
Spc suppl protection certif: C20090039 282 |